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Abstract
Time to full publication of studies of anti-cancer medicines 
for breast cancer and the potential for publication bias: a 
short systematic review
A Takeda,* E Loveman, P Harris, D Hartwell and K Welch
Southampton Health Technology Assessments Centre (SHTAC), Southampton, UK
*Corresponding author
Objectives: To identify the expected delay between 
publication of conference abstracts and full publication 
of results from trials of new anti-cancer agents for 
breast cancer and to identify whether there are any 
apparent biases in publication and reporting.
Data sources: Major electronic databases were 
searched to identify randomised controlled trials (RCTs) 
of the selected interventions for the treatment of breast 
cancer.
Review methods: A systematic review was conducted 
according to standard methods. Data were extracted 
from the included studies using a predesigned and 
piloted data extraction template.
Results: Six anti-cancer treatments for breast cancer 
were included in the review: docetaxel, paclitaxel, 
trastuzumab, gemcitabine, lapatinib and bevacizumab. 
The literature searches generated 1556 references, 
from which 71 publications were retrieved and 
screened for inclusion. Screening identified 41 
publications of 18 RCTs with at least one arm of 
treatment meeting the inclusion criteria for the review. 
Of the 18 included RCTs, only four publications (from 
three RCTs) reported the same outcomes in both 
an abstract and a full publication. Time between the 
abstract and full publication was 5 months in two cases, 
7 months in one case and 19 months in one case (overall 
mean delay = 9 months). Eleven trials were identified 
that have not currently published in a full publication the 
data presented in an abstract or conference proceeding. 
The duration between publication of the abstracts and 
the end of August 2007 varied from 3 months to 38 
months (mean delay 16.5 months). The longest delays in 
publication were for trials investigating gemcitabine (38 
months) or bevacizumab (33 months). Observational 
analysis of the published and unpublished trials did 
not indicate any particular biases in terms of whether 
positive results were more likely to be fully published 
than non-significant ones.
Conclusions: It was surprising that only three of the 18 
relevant RCTs had one or more full papers that reported 
the same outcome measures (and stage of analysis) as 
an earlier conference abstract. However, a limitation 
of this review is the small number of studies included. 
With a larger sample size than that in the present 
report, investigation into the effect of publication delay 
on decision-making might be feasible. Future research 
should include extension of this work to other anti-
cancer drugs and investigation into the reasons for 
lengthy delays to full publication noted for some trials.Health Technology Assessment 2008; Vol. 12: No. 32
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
v
  List of abbreviations   ..................................  vii
  Executive summary   ................................... i x
1  Aim of the review   ......................................  1
2  Background   ...............................................  3
Description of underlying health problem  
and treatments   ......................................  3
Current NICE guidance for breast  
cancer   ....................................................  3
Publication bias    ..........................................  4
Rationale for the study   ..............................  5
3  Research methods    ....................................  7
Identification of anti-cancer drugs for breast 
cancer   ....................................................  7
Search strategy    ...........................................  7
Study inclusion    .........................................  8
Inclusion criteria    ........................................  8
Data extraction   ..........................................  8
4  Results   .......................................................  9
Interventions included   ..............................  9
Included RCTs   ...........................................  9
Assessment of mean time between  
publication of abstracts and publication of 
full paper   ...............................................  9
Comparison of results of abstracts and full 
papers   .................................................... 1 2
Ongoing trials    ............................................ 1 4
5  Discussion   .................................................. 1 5
Time to publication   ................................... 1 5
Direction of effect   ...................................... 1 6
Limitations of the report   ........................... 1 6
6  Conclusions    ................................................ 1 7
Research recommendations   ....................... 1 7
  Acknowledgements   ................................... 1 9
  References   ................................................. 2 1
Appendix 1 MEDLINE search strategy for  
gemcitabine   ................................................. 2 5
Appendix 2 Data extractions   ....................... 2 7
Appendix 3 Flow chart of systematic review 
process    ........................................................ 4 3
Appendix 4 Details of related ongoing trials    .. 4 5
Health Technology Assessment reports  
published to date    ....................................  47
Health Technology Assessment 
Programme    .............................................  65
ContentsHealth Technology Assessment 2008; Vol. 12: No. 32
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
vii
List of abbreviations
AC adjuvant chemotherapy
ASCO American Society of Clinical 
Oncology
BNF British National Formulary
CI confidence interval
CNS central nervous system
DFS disease-free survival
EMeA European Medicines Agency
EPAR European Public Assessment 
Reports
ER estrogen receptor
HER2+ HER2 protein positive
HR hazard ratio
HTA Health Technology Assessment
IAUC incremental ara under the curve
ITT intention to treat
NICE National Institute for Health and 
Clinical Excellence
ORR overall response rate
PFS progression-free survival
PP PowerPoint presentation
RCT randomised controlled trial
RR relative risk
RT radiotherapy
STA Single Technology Appraisal
TDR time to distant recurrence 
TTP time to (disease) progression
TTR time to recurrence
All abbreviations that have been used in this report are listed here unless the abbreviation is well 
known (e.g. NHS) or it has been used only once or it is a non-standard abbreviation used only in 
figures/tables/appendices, in which case the abbreviation is defined in the figure legend or in the 
notes at the end of the table.Health Technology Assessment 2008; Vol. 12: No. 32
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
ix
Executive summary
Background
In recent years the development of targeted 
therapies has led to an increase in the number of 
specialised anti-cancer treatments. The National 
Institute for Health and Clinical Excellence (NICE) 
has issued guidance on many such treatments 
and continues to assess new drugs as they become 
licensed. Because the technologies are often 
undergoing market authorisation or have only 
recently been licensed, the evidence base is usually 
limited. Often there will be only one randomised 
controlled trial assessing efficacy, and this may not 
be fully published at the time of appraisal. It is 
therefore important to establish the pattern of full 
publications to inform the developing methodology 
for reviews in this fast moving area.
Methods 
The methodology for this project was constrained 
by the tight timescales and limited resources 
allowed for a short report (i.e. approximately 
one-third of that allowed for a full technology 
appraisal). A full search of existing NICE 
technology appraisals of anti-cancer drugs for 
breast cancer was undertaken by one reviewer and 
checked by a second. Because of time constraints 
these were then restricted to those that had been, 
or were due to be, appraised under the Single 
Technology Appraisal (STA) programme at NICE. 
A comprehensive search strategy was developed 
to identify RCTs of the selected interventions 
for the treatment of breast cancer. The following 
databases were searched for published RCTs: Ovid 
MEDLINE; EMBASE; Database of Abstracts of 
Reviews of Effectiveness; Cochrane Database for 
Systematic Reviews; the Cochrane Central Register 
of Controlled Trials; and ISI Proceedings. As 
there were previous NICE technology assessments 
for many of the interventions, the searches were 
limited to studies published after the cut-off dates 
of searching in the previous publications until 
August 2007. Dates were therefore from 2002 for 
capecitabine, from 2005 for docetaxel, from 2006 
for paclitaxel, and from 2000 for trastuzumab 
and vinorelbine. For those technologies that are 
currently in the process of being appraised by 
NICE, searches were undertaken from 5 years 
before the date of the first license of the technology 
up until August 2007. 
The National Research Register and a US National 
Institutes of Health register (ClinicalTrials.gov) 
were searched to identify RCTs in progress. 
Websites of international conferences were 
also searched, from 5 years prior to the date of 
marketing authorisation until the present date.
Titles and abstracts of identified references were 
screened systematically against the inclusion 
criteria by one reviewer and checked by a second. 
Inclusion criteria detailed the patient groups, 
interventions and comparators defined by NICE, 
with no restriction on the outcome measures used. 
Full manuscripts of all selected citations were 
retrieved and assessed by one reviewer and checked 
by a second reviewer against the inclusion criteria. 
Disagreements over study inclusion were resolved 
by consensus or if necessary through arbitration 
by a third reviewer. Data were extracted from the 
included studies by one reviewer and checked 
by a second reviewer. Any disagreements were 
resolved by consensus, if necessary involving a third 
reviewer.
Results
Six anti-cancer treatments for breast cancer were 
included in the review. Interventions for early 
breast cancer were docetaxel, paclitaxel and 
trastuzumab and interventions for advanced 
or metastatic breast cancer were gemcitabine, 
lapatinib and bevacizumab. The literature searches 
and checking of reference lists generated 1556 
references, of which 71 publications were retrieved 
and screened for inclusion. Screening identified 
41 publications of 18 RCTs with at least one arm 
of treatment meeting the inclusion criteria for the 
review. 
Of the 18 included RCTs, only four publications 
(from three RCTs) reported the same outcomes 
in both an abstract and a full publication. Time 
between the abstract and full publications was 5 Executive summary
x
months in two cases, 7 months in one case and 
19 months in one case (overall mean delay = 9 
months). 
Eleven trials were identified that have not currently 
published in a full publication the data presented 
in an abstract or conference proceeding. The 
duration between publication of the abstracts and 
the end of August 2007 varied from 3 months to 
38 months (mean delay 16.5 months). The longest 
delays in publication were for trials investigating 
gemcitabine (38 months) or bevacizumab (33 
months). 
Conclusions
Given that the searches identified 18 relevant RCTs 
it was rather surprising that only three of these 
had one or more full papers which reported the 
same outcome measures (and stage of analysis) 
as an earlier conference abstract. Observational 
analysis of the published and unpublished trials 
did not indicate any particular biases in terms of 
whether positive results were more likely to be fully 
published than non-significant ones. However, a 
limitation here was the small number of studies 
included in this report. Health Technology Assessment 2008; Vol. 12: No. 32
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
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Chapter 1 
Aim of the review
T
he aim of this short report, which was 
commissioned by the NIHR Health 
Technology Assessment (HTA) Programme, was to 
identify the expected delay between publication of 
conference abstracts and full publication of results 
from trials of new anti-cancer agents for breast 
cancer. A secondary aim of the research was to 
identify whether there are any apparent biases in 
publication and reporting.Health Technology Assessment 2008; Vol. 12: No. 32
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
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Chapter 2  
Background
Description of underlying 
health problem and 
treatments
In 2004 there were 36,939 new cases of breast 
cancer in women in England, which represents a 
crude rate of 144.6 per 100,000 women.1 Figures 
for Wales are available for 2005, when there were 
2364 new registrations or a rate of 155.4 per 
100,000 women. These figures equate to age-
standardised rates per 100,000 population of 120.7 
(95% CI 119.5–121.9) for England and 120.8 (95% 
CI 115.9–125.7) for Wales.2 A recent review by 
the Office for National Statistics found a 20-year 
survival rate of 64% for women diagnosed with 
breast cancer between the ages of 50 and 69.3 
The survival rates for breast cancer have shown 
great improvements since 1991 and these changes 
are consistent with earlier and better diagnosis 
and improvements in the management of breast 
cancer with the use of more effective treatments.4 
Recent advances in molecular oncology and 
sequencing of the human genome have led to 
greater understanding of the transformation and 
growth of malignant cells.5 Drug development is 
therefore moving away from systemic cytotoxic 
chemotherapy towards novel targeted agents. 
These act by inhibiting specific requirements or 
functions of tumour cells, and some are inhibitory 
to normal tissues such as vascular endothelial cells.6 
Targeted cancer therapies include several 
types of drugs such as monoclonal antibodies 
and apoptosis-inducing drugs.7 For example, 
trastuzumab and lapatinib target the HER2 gene, 
whereas bevacizumab targets the new blood 
vessels that allow tumours to grow.8 Most targeted 
therapies work in the same way as antibodies 
made by the immune system and so they are often 
referred to as immune-targeted therapies.9 
In the last 10–15 years the development of targeted 
therapies has led to an increase in the number 
of specialised anti-cancer treatments. The first 
monoclonal antibody to be licensed in the UK for 
cancer was rituximab, for high-grade lymphoma in 
1998.10 Trastuzumab was approved by the National 
Institute for Health and Clinical Excellence (NICE) 
for the treatment of advanced breast cancer in 
200211 and for early breast cancer in 2006.12 Other 
treatments for breast cancer that have emerged 
in recent years include antimetabolites such as 
gemcitabine and a microtubule-interacting agent 
(vinorelbine), in addition to older drugs such 
as the taxanes paclitaxel and docetaxel.13 NICE 
has issued guidance on all of these drugs and 
continues to assess new treatments as they become 
licensed.11,14–17 Many more targeted therapies are 
still in the preclinical testing stage7 and it is likely 
that these will be used in combined therapy with 
existing cytotoxic drugs.6 The addition of these 
treatments considerably increases the cost to the 
health service of treating the disease. In addition 
to the costs of the drugs themselves there may also 
be the costs of administration and monitoring.18 
Timely appraisal of such drugs is therefore of 
interest to NICE.
Current NICE guidance 
for breast cancer
The NICE Single Technology Appraisal (STA) 
Programme aims to provide a rapid appraisal 
of new technologies and to allow guidance to be 
made available to the NHS. Chemotherapy drugs 
have been among the first technologies to be 
appraised under this new system. To make a fair 
and transparent appraisal of a technology it is 
important to evaluate all of the available evidence 
on its clinical effectiveness and cost-effectiveness. 
This should include an appraisal of the methods 
and results of studies. Because the technologies 
are often undergoing market authorisation or 
have only recently been licensed, the evidence 
base is usually limited. Often there will be only 
one randomised controlled trial (RCT) assessing 
efficacy. This may not be fully published at the 
time of appraisal (e.g. the recent appraisal of 
gemcitabine for metastatic breast cancer17) and 
may never be fully published in a peer-reviewed 
publication. Background
4
Publication bias
There are four main areas of the literature relevant 
to this review: time to publication; publication 
bias in terms of direction of results; differences in 
results reported in abstracts and full publications; 
and differences in quality of reporting between 
abstracts and full publications. 
A recently published Cochrane review19 
investigated the time lag to publication for results 
of clinical trials. The systematic review identified 
two review articles of 196 trials. The systematic 
review found that studies with results that 
statistically significantly favoured the experimental 
arm tended to take 4–5 years to publish, whereas 
trials with null or negative results (i.e. not 
statistically significant or statistically significantly 
favouring the control arm) were generally 
published 6–8 years following trial inception. One 
of the included reviews investigated AIDS trials 
and the other examined the time interval between 
the date of a trial’s ethics committee approval (in 
Australia, between 1979 and 1988) and the date of 
first publication in a peer-reviewed journal. The 
Cochrane review19 did not include any reviews that 
were specifically investigating publication bias in 
anti-cancer drug trials. The reviewers did identify 
one such study, published in 1987, but excluded 
it because the analysis of time to publication was 
not available separately for the registered and 
published cohorts of the trials. 
Krzyzanowska and colleagues20 conducted a 
survey of 510 abstracts from large phase III RCTs 
presented at American Society of Clinical Oncology 
(ASCO) meetings between 1989 and 1998. Their 
searches found that 26% of the trials reported in 
abstracts were not published in full within 5 years 
of presentation at a meeting. Krzyzanowska and 
colleagues found considerable evidence of bias 
in favour of full publication of significant results 
(p ≤ 0.05 for primary outcome), with 81% being 
published within 5 years compared with 68% of 
studies with non-significant results. The authors 
followed up a number of studies that had not 
been published in full to find the reasons for this; 
the most frequent reason given was lack of time, 
funding or other resources. 
A recent Cochrane review21 found that only 63% 
of results from 79 reports (29,729 abstracts) 
describing randomised or controlled clinical 
trials are published in full. Results that showed 
statistical significance, favoured the experimental 
treatment or were from randomised or controlled 
clinical trials were more frequently published as full 
publications than other kinds of results. The review 
included summary reports that examined the 
subsequent rate of full publication of results related 
to biomedical science which were initially published 
in abstract or summary forms. The review included 
subject areas as far-ranging as marine biology, 
gastroenterology and emergency medicine. It 
is therefore not possible to draw any specific 
conclusions relating to anti-cancer therapies from 
this review.21 
Other work on publication bias followed the fate of 
abstracts from the 1984 ASCO meeting.22 However, 
this study followed up all conference abstracts to 
assess publication bias and did not specifically focus 
on time to full publication of RCTs. It is also likely 
that trends in publication time have changed over 
the past 15–20 years. A systematic review published 
in 2003 investigated publication bias around the 
acceptance rates of abstracts and their subsequent 
full publication.23 The review searched for studies 
that identified the publication route of abstracts 
submitted to conferences. Again, this study was 
concerned with following all abstracts, not just 
those reporting RCTs. 
Chan and colleagues24 investigated selective 
reporting and publication bias in 102 randomised 
trials, comparing registered protocols with 
published reports. Their review included all 
clinical studies approved by an ethical committee 
in a particular time period, and results were not 
presented separately for oncology trials. 
Previous HTA methodology work has assessed 
the link between data in conference abstracts 
and data in full publications. Dundar and 
colleagues25,26 carried out an audit to assess the use 
of conference abstracts in Technology Assessment 
Reports compiled for NICE, and investigated 
whether data presented in the conference abstract 
differed substantially from that reported in the 
full publication. Rosmarakis and colleagues27 have 
also documented differences in outcomes reported 
by abstracts and full publications in the fields of 
infectious diseases and microbiology. 
Quality of reporting in abstracts is generally more 
limited than that in full papers. Hopewell and 
colleagues28 identified RCTs presented at the 1992 
ASCO conference and searched the literature to 
find corresponding full publications. The focus 
of their work was on identifying differences 
between quality of reporting in conference 
abstracts and quality of reporting in the later full Health Technology Assessment 2008; Vol. 12: No. 32
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
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publications. Their results found that only 46% 
of the 37 identified trials had the same number 
of participants randomised in the abstract and 
full publication, and only 22% reported the 
same number analysed. The majority of abstracts 
reported results from ongoing trials, whereas 82% 
of the trials in the full publication were closed 
to follow-up. Hopewell and colleagues reported 
great limitations in assessing trial quality based 
on information presented in abstracts. Only 
14% of the abstracts reported intention to treat 
(ITT) analysis, compared with 46% of the full 
publications. In an attempt to encourage more 
complete reporting in abstracts, Krzyzanowska 
and colleagues29 modified the guidelines for the 
conduct and reporting of randomised trials to 
apply to abstracts submitted to ASCO meetings.
Rationale for the study
With the development of new chemotherapy agents 
the NICE STA process is likely to see a rise in the 
number of drugs gaining marketing authorisation 
over the coming years. This will lead to a 
concurrent increase in the number of systematic 
reviews being carried out on more limited evidence 
bases, compared with standard technology 
appraisals in which more fully published trial data 
are usually available. NICE has already issued 
guidance for cases when full peer-reviewed trial 
data are not available.17 It is therefore important to 
establish the pattern of full publications to inform 
the developing methodology for reviews in this 
fast-moving area. Health Technology Assessment 2008; Vol. 12: No. 32
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
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Chapter 3  
Research methods 
A 
systematic review was conducted according to 
the methods outlined in a research protocol 
submitted to the HTA programme in July 2007. 
The key objective of the review was to identify the 
delay between publication of conference abstracts 
and full publication of results from RCTs of new 
anti-cancer agents for breast cancer. The secondary 
objective was to identify whether there are any 
apparent biases in publication and reporting. 
Identification of anti-cancer 
drugs for breast cancer
A full search of existing NICE technology 
appraisals of anti-cancer drugs for breast cancer 
was undertaken by one reviewer and checked 
by a second. This included technologies that 
were currently in the process of being appraised 
by NICE. Eleven areas of NICE guidance were 
identified for eight anti-cancer drugs (three drugs 
had guidance both for early breast cancer and 
for advanced/metastatic breast cancer). As such, 
the number of related references likely to require 
screening was beyond the capacity available for this 
short report. During this early stage of the review 
a decision was therefore taken to limit the number 
of technologies to those that had been, or were 
due to be, appraised under the STA programme 
at NICE. Such drugs tend to be appraised closer 
to their marketing authorisation dates than those 
considered under the more established Multiple 
Technology Appraisal (MTA) programme, and 
there is generally less published evidence available 
for them. Given the limited time available it was 
therefore deemed more relevant to focus on drugs 
appraised under these conditions, to obtain an 
indication of the data available and any publication 
bias that might affect the STA programme. 
This reduced the number to six interventions 
that had received, or were being considered for, 
NICE guidance. The list of anti-cancer drugs that 
were identified and included is shown in Table 1. 
For each technology identified a search of the 
European Medicines Agency (EMeA) website, the 
British National Formulary (BNF) and the relevant 
manufacturers’ websites was made to clarify the UK 
license details. The NICE website and the EMeA 
website [and the European Public Assessment 
Reports (EPARs) identified from the EMeA 
website] were also used to search for any additional 
information on the licensed agents and to identify 
RCTs of the relevant drugs.
Search strategy
A comprehensive search strategy was developed to 
identify RCTs of the interventions for the treatment 
of breast cancer. The search strategy aimed to 
systematically identify all relevant studies that 
met the inclusion criteria given in Table 1. The 
strategy for MEDLINE, shown in Appendix 1, was 
modified for use in other databases. The following 
databases were searched for published RCTs: 
Ovid MEDLINE; EMBASE; Database of Abstracts 
of Reviews of Effectiveness (DARE); Cochrane 
Database for Systematic Reviews (CDSR); Cochrane 
Central Register of Controlled Trials; and ISI 
Proceedings. The National Research Register 
(NRR) and ClinicalTrials.gov were searched to 
identify RCTs in progress. Bibliographies of 
retrieved articles were also checked for additional 
studies. 
Websites of international conferences such as the 
American Society of Clinical Oncology (ASCO) 
and the San Antonio Breast Cancer Symposium 
(SABCS) were also searched to identify relevant 
conference proceedings and abstracts. These 
were searched from 5 years prior to the date of 
marketing authorisation until the present date. 
The internet was also searched using trial names/
identifiers in internet search engines such as 
Google.
As there were previous NICE technology 
assessments for many of the interventions, the 
searches were limited to studies published after 
the cut-off dates of searching in the previous 
publications until August 2007. Dates were 
therefore from 2002 for capecitabine, from 2005 
for docetaxel, from 2006 for paclitaxel, and from 
2000 for trastuzumab and vinorelbine. For those 
technologies that are currently in the process 
of being appraised by NICE, searches were 
undertaken from 5 years before the date of the first 
license of the technology up until August 2007. Research methods
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Study inclusion 
All references identified by the literature searches 
were imported into a Reference Manager 
bibliographic database. After deleting duplicate 
references from the database, the title and (where 
available) abstract of each reference was screened 
systematically against the inclusion criteria 
reported in Table 1, to assess the relevance of 
the study for inclusion in the review. This was 
undertaken by one reviewer and checked by a 
second reviewer. Full manuscripts of all selected 
citations were retrieved and assessed by one 
reviewer and checked by a second reviewer against 
the inclusion criteria. Disagreements over study 
inclusion were resolved by consensus or if necessary 
through arbitration by a third reviewer.
Inclusion criteria
The planned inclusion/exclusion criteria for the 
systematic review are shown in Table 1. There was 
no restriction placed on the outcome measures 
used at this stage of the project. 
Data extraction
Data were extracted from the included studies 
using a predesigned and piloted data extraction 
template to report information on the month and 
year of publication of each included study, the 
numbers of participants in each study arm (to allow 
identification of linked studies) and key outcome 
data from each study (see Appendix 2). Data from 
each study were extracted by one reviewer and 
checked by a second reviewer. Any disagreements 
were resolved by consensus, if necessary involving a 
third reviewer. Given the limited resources available 
it was only possible to extract data on the key 
outcomes of studies, giving preference to overall 
survival and any measures relating to time to 
disease progression. Full publications and abstracts 
were linked by reference to trial identifiers, trial 
arms, numbers of participants and any other 
available information. For each intervention, 
information on the date of any decisions made by 
NICE was also noted.
TABLE 1  Inclusion criteria for the systematic review 
Patients
Adults (over 18 years of age) with breast cancer (meeting specific disease stage 
criteria as appropriate)
Interventions (alone or in 
combination according to 
licensed indications)
Gemcitabine for advanced/metastatic cancer
Docetaxel for early cancer
Paclitaxel for early cancer
Trastuzumab for early cancer
Bevacizumab for advanced/metastatic cancer
Lapatinib for advanced/metastatic cancer
Comparator Any, including placebo
Design Randomised controlled trialsHealth Technology Assessment 2008; Vol. 12: No. 32
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
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Chapter 4  
Results
Interventions included
Six anti-cancer treatments for breast cancer were 
included in the review. Of these treatments three 
were for early breast cancer and three were for 
advanced or metastatic breast cancer. Interventions 
for early breast cancer were docetaxel, paclitaxel 
and trastuzumab and interventions for advanced 
or metastatic breast cancer were gemcitabine, 
lapatinib and bevacizumab. Docetaxel, paclitaxel, 
trastuzumab and gemcitabine have been appraised 
by NICE; two were used as monotherapy 
and two were used in combination with other 
treatments (Table 2). Bevacizumab and lapatinib 
have appraisals in process. To keep this review 
relevant to the NICE appraisal process, only 
these applications for each of the respective drugs 
were used. For the two interventions that are 
appraisals in process we have reported all of the 
treatment combinations identified in the literature 
for bevacizumab, and restricted lapatinib to the 
treatment combination described in the ongoing 
STA. For two of the anti-cancer drugs for early 
breast cancer an additional indication (as per the 
NICE guidance) required the diagnosis to include 
node-positive disease (Table 2).
TABLE 2  Interventions and their indications considered by NICEa
Breast cancer drug Indications considered by NICE
Early breast cancer
Docetaxel In combination with doxorubicin and cyclophosphamide for women diagnosed with 
operable node-positive breast cancer
Paclitaxel As monotherapy for node-positive breast cancer
Trastuzumab Monotherapy as second-line treatment
Advanced/metastatic cancer
Gemcitabine In combination with paclitaxel
Lapatinib In combination with capecitabine
Bevacizumab In combination with capecitabine, docetaxel, paclitaxel or cyclophosphamide and 
methotrexate
a  Lapatinib and bevacizumab are currently ‘appraisals in progress’; therefore, indications considered here reflect those 
identified in the literature for bevacizumab and the combination in NICE’s scope for lapatinib.
Included RCTs
The literature searches (including checking 
reference lists) generated 1556 references, whose 
titles and abstracts were inspected. The full process 
is documented in the flow chart in Appendix 
3. A total of 71 publications were retrieved and 
screened for inclusion. Of these, 30 publications 
were excluded according to the review criteria and 
41 publications of 18 RCTs included at least one 
arm of treatment meeting the indications noted 
in Table 2 and therefore met the inclusion criteria 
for the review. The breakdown in respect to each 
individual treatment was as follows: docetaxel, 
three RCTs; paclitaxel, two RCTs; trastuzumab, 
three RCTs; gemcitabine, two RCTs; lapatinib, 
three RCTs; bevacizumab, five RCTs.
Assessment of mean time 
between publication of 
abstracts and publication 
of full paper
Tables 3–8 illustrate, for each intervention, the 
mean time between publication of an abstract and Results
10
publication of the full paper for each trial. In some 
cases a trial has reported key outcomes in abstract 
form but no full publication of these results has 
been identified; for these a calculation of the mean 
time between publication of the abstract and the 
present date has been made. Some trials have 
reported outcomes in more than one abstract and 
full publication; where this has occurred careful 
matching of each abstract with its respective full 
publication was made and a calculation undertaken 
for each. Matching was based on the trial identifier 
number, where available, numbers of participants, 
description of treatment arms and outcomes and 
any other information available. Calculation of 
time to publication was restricted to abstracts 
and corresponding full papers that reported 
measures of overall survival or aspects of disease 
progression. Abstracts that only reported baseline 
characteristics, adverse events or quality of life 
scores were not included in the analysis.
As can be seen in the above tables, of the 18 
included trials only three trials (GEPARDUO,36,37 
HERA48–51 and INT 014842,43) had a conference 
abstract and full publication sharing a common 
outcome (the HERA trial has two different abstracts 
linked to two full publications). Some of the trials 
reported interim analyses of their data in one 
publication (usually the abstract) and full analysis 
in another linked publication.30,31,40,41,45,46 In others, 
abstracts and full publications simply reported 
different outcomes from the range assessed 
within the trial.32–35,58,59,64,65 Therefore it would 
be inappropriate to include these in any overall 
assessment of length of time between publications. 
Of the four sets of publications (from three trials) 
that reported the same outcomes in both an 
abstract and full publication, the time between the 
abstract and full publications was 5 months for two 
RCTs (docetaxel, GEPARDUO;36,37 trastuzumab, 
HERA48,49), 7 months for one RCT (trastuzumab, 
HERA50,51) and 19 months for the other RCT 
(paclitaxel, INT 014842,43). The mean time to full 
publication for these four sets of publications from 
the three trials is therefore 9 months. 
Eleven trials were identified that have not currently 
published in a full publication the data presented 
in an abstract or conference proceeding. The 
duration between publication of the abstracts and 
the end of August 2007 varies from 3 months 
to 38 months (see Table 9). Seven trials have not 
published their data in full after at least 12 months 
TABLE 3  Time between publication of abstract and publication of full paper for docetaxel trials
Trial identifier and 
interventions Publication details and status Date published
Estimated time delay 
between abstract and full 
paper
BCIRG 001
Docetaxel plus doxorubicin 
and cyclophosphamide vs 
fluorouracil plus doxorubicin and 
cyclophosphamide
(1) Nabholtz30 – Abstract (first 
interim analysis)
May 2002 37 months 
(2) Martin31 – Full paper (second 
interim analysis)
June 2005
NSABP B-27
Doxorubicin and 
cyclophosphamide plus 
docetaxel vs doxorubicin and 
cyclophosphamide
(1) Bear32 – Abstract  December 2001 These studies do not report a 
common outcome
(2) Bear33 – Full paper  November 2003
(3) Bear34 – Abstract December 2004
(4) Bear35 – Full paper May 2006
GEPARDUO 
Doxorubicin plus 
cyclophosphamide followed by 
docetaxel vs doxorubicin plus 
docetaxel
(1) von Minckwitz36 – Abstract 
(reporting pathological response)
May 2002 5 months
(2) Jackisch37 – Full paper (reporting 
pathological response)
October 2002
(3) von Minckwitz38 – Full paper. 
No overall survival or time to 
progression data
April 2005 Not applicable (no 
corresponding abstract)
(4) Blohmer39 – Abstract (analysis of 
overall survival data)
March 2006 Time awaiting full 
publication = 18 months as of 
31 August 2007Health Technology Assessment 2008; Vol. 12: No. 32
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TABLE 4  Time between publication of abstract and publication of full paper for paclitaxel trials
Trial identifier and 
interventions Publication details and status Date published
Estimated time delay 
between abstract and 
full paper
INT 0148
Cyclophosphamide, doxorubicin 
and paclitaxel vs cyclophosphamide 
and doxorubicin
(1) Henderson40 – Abstract (interim 
analysis)
May 1998 58 months 
(2) Henderson41 – Full paper March 2003
(3) Sartor42 – Abstract (subgroup 
analysis 1)
June 2003 19 months
(4) Sartor43 – Full publication 
(subgroup analysis 1)
January 2005
(5) Hayes44 – Abstract (subgroup 
analysis 2)
June 2006 Time awaiting full 
publication = 15 months as 
of 31 August 2007
NSABP B-28
Cyclophosphamide, doxorubicin 
and paclitaxel vs cyclophosphamide 
and doxorubicin
(1) Mamounas45 – Abstract (interim 
analysis)
November 2000  55 months
(2) Mamounas46 – Full paper June 2005
(3) Mamounas47 – Abstract (adverse 
events)
June 2003 Not applicable
TABLE 5  Time between publication of abstract and publication of full paper for trastuzumab trials
Trial identifier and interventions Publication details and status Date published
Estimated time delay 
between abstract and 
full paper
HERA
Trastuzumab vs observation
(1) HERA group48 – Abstract 
(interim analysis)
May 2005 5 months
(2) Piccart-Gebhart49 – Full 
paper (interim analysis)
October 2005
(3) Smith50 – Abstract June 2006 7 months
(4) Smith51 – Full paper January 2007
BCIRG 006
Doxorubicin and cyclophosphamide 
plus docetaxel vs doxorubicin and 
cyclophosphamide plus docetaxel 
plus trastuzumab, vs docetaxel plus 
carboplatin plus trastuzumab (TCH)
(1) Slamon52 – Abstract (first 
interim analysis)
December 2005 Time awaiting full 
publication of most 
recent abstract (2) = 5 
months as of 31 August 
2007
(2) Slamon53 – Abstract (second 
interim analysis)
April 2007
PACS 04
Trastuzumab vs observation (second 
randomisation following adjuvant 
treatments)
(1) Spielmann54 – Abstract June 2006 Time awaiting full 
publication = 15 months 
as of 31 August 2007
since the abstract data were presented, and four 
of these remain unpublished after 21 months or 
more. The data in Table 9 are presented under 
subcategories of the interventions evaluated in 
the trials, showing that the trials for the two drugs 
gemcitabine and bevacizumab have the longest 
time without full publication. 
The range of results found in this investigation 
makes it difficult to establish what an estimated 
time to publication for these sorts of drugs might 
be. The mean time awaiting publication for these 
drugs is 16.5 months, to the end of August 2007. 
This estimate is based on a small sample that 
has a large range (3–38 months). The calculation Results
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TABLE 6  Time between publication of abstract and publication of full paper for gemcitabine trials
Trial identifier and interventions Publication details and status Date published
Estimated time delay 
between abstract and full 
paper
JHQG
Gemcitabine and paclitaxel vs 
paclitaxel
(1) O’Shaughnessy55 – Abstract June 2003 Time awaiting full publication 
of most recent abstract 
(3) = 38 months as of 31 
August 2007
(2) Albain56 – Abstract July 2004
(3) Moinpour57 – Abstract July 2004
B9E-MC-S197
Gemcitabine and paclitaxel (two 
groups) vs gemcitabine and 
docetaxel
(1) Khoo58 – Abstract (no 
efficacy data)
July 2004 Not applicable
(2) Khoo59 –Full paper August 2006
TABLE 7  Time between publication of abstract and publication of full paper for lapatinib trials
Trial identifier and interventions Publication details and status Date published
Estimated time delay 
between abstract and 
full paper
NCT00078572
Lapatinib plus capecitabine vs 
capecitabine
(1) Geyer60 – Full publication 
(interim data)
December 2006 Not applicable
(2) Geyer61 –Abstract  June 2007 Time awaiting full 
publication (from 
abstract) = 3 months as 
of 31 August 2007
Sherill
Lapatinib plus capecitabine vs 
capecitabine
(1) Sherrill62 – Abstract June 2007 Time awaiting full 
publication = 3 months as 
of 31 August 2007
Cameron
Lapatinib plus capecitabine vs 
capecitabine
(1) Cameron63 – Abstract December 2006 Time awaiting full 
publication = 9 months as 
of 31 August 2007
does not take into account any differences in 
the interventions, the manufacturers or the trial 
sponsors and any publication bias due to positive 
or negative results. However, it would appear that 
for the majority of the trials there is at least a 
12-month delay for full publication, to the end of 
August 2007. 
Comparison of results of 
abstracts and full papers
Four sets of publications from three trials 
(GEPARDUO,36,37 HERA48–51 and INT 014842,43) 
reported the same outcome in an abstract and a 
full publication. Of these, only two (both sets of 
publications from the HERA trial48–51) reported 
data on overall survival and time to disease 
progression. Of the other two linked studies, 
one was a publication of a secondary outcome 
(pathological complete response36,37) and one was 
a subgroup analysis of radiotherapy delivery.42,43 
Because of the limitations of this review as a short 
report, these last two outcomes were not data 
extracted. The interim analysis of data in the 
HERA trial48,49 for overall survival and for time to 
disease progression was the same in the abstract 
and the linked full publication. The 2-year follow-
up analysis of data from patients receiving a 
years’ treatment in the HERA trial50,51 was also the 
same in the abstract and the corresponding full 
publication.
Trials reporting interim 
results in abstracts and final 
results in full publication
Outcomes reported within linked publications in 
which one paper reported interim results and one 
reported full results have also been investigated Health Technology Assessment 2008; Vol. 12: No. 32
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
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TABLE 8  Time between publication of abstract and publication of full paper for bevacizumab trials
Trial identifier and interventions Publication details and status Date published
Estimated time delay 
between abstract and full 
paper
Miller
Bevacizumab plus capecitabine vs 
capecitabine
(1) Miller64 – Abstract (baseline 
data only)
December 2002 Not applicable
(2) Miller65 – Full paper February 2005
Overmoyer
Bevacizumab plus docetaxel vs 
docetaxel
(1) Overmoyer66 – Abstract 
(reports tumour size)
July 2004 Time awaiting full publication 
since most recent 
abstract = 33 months as of 31 
August 2007 (2) Overmoyer67 – Abstract 
(reports tumour size)
December 2004
E2100
Bevacizumab plus paclitaxel vs 
paclitaxel
(1) Miller68 – Abstract  December 2005 Time awaiting full publication 
(from abstract (1) reporting 
overall survival data) = 21 
months as of 31 August 2007
(2) Wagner69 – Abstract (quality 
of life outcomes)
December 2006 Not applicable
Lyons
Bevacizumab plus docetaxel vs 
docetaxel
(1) Lyons70 – Abstract (reports 
tumour size)
June 2006 Time awaiting full 
publication = 15 months as of 
31 August 2007
Burstein
Bevacizumab plus 
cyclophosphamide and 
methotrexate vs cyclophosphamide 
and methotrexate
(1) Burstein71 – Abstract 
(reports tumour size)
December 2005 Time awaiting full 
publication = 21 months as of 
31 August 2007
TABLE 9  Length of time since publication of trial data in abstract form to the end of August 2007
Trial identifier Time since abstract published Statistical significance of trial results
Docetaxel for early breast cancer
GEPARDUO39 18 months Not significant
Trastuzumab for early breast cancer
BCIRG 00652,53 5 months Significant 
PACS 0454 15 months No overall survival data
Gemcitabine for advanced/metastatic breast cancer
JHQG55–57 38 months Significant 
Lapatinib for advanced/metastatic breast cancer
NCT0007857260,61 3 months Not significant 
Sherrill62 3 months Significant 
Cameron63 9 months Not reported
Bevacizumab for advanced/metastatic breast cancer
Lyons70 15 months Not reported
E210068,69 21 months Significant 
Burstein71 21 months Not reported
Overmoyer66,67 33 months Not reportedResults
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for direction of the effect shown. Although it 
would not be meaningful to compare the actual 
results of these publications, because one is 
clearly published at an interim point in time, it 
is meaningful to consider if the direction of the 
results is similar. Three trials reported interim data 
in an abstract and final data in a full publication. 
Two of these were trials of paclitaxel (INT0148;40,41 
NSABP-B2845,46) and one was of docetaxel (BCIRG 
00130,31). Although the docetaxel trial BCIRG001 
reported a second interim analysis rather than a 
full final analysis, it has been included here as it 
reports the same outcome measures as the abstract. 
The full paper acknowledges that a further analysis 
would be required to confirm and extend their 
estimated 5-year survival rate.31 
Paclitaxel
Data presented for overall survival in the INT0148 
trial40,41 were positive for treatment with paclitaxel 
in both the abstract40 and the full results.41 
Observation of the data suggests that there was a 
better effect on survival at the point of the interim 
analysis than in the full publication (see Appendix 
2 for further details). Time to disease progression 
was reported in the full publication. These data 
were not reported in the abstract, although it 
was stated that the addition of paclitaxel had a 
significant impact on disease-free survival. The 
NSABP-B28 trial45,46 reported no statistically 
significant differences between treatment arms 
in survival or death at the interim analysis in the 
abstract.45 There was a non-statistically significant 
reduction in the death rate reported in the full 
publication.46 Disease-free survival in this trial was 
reported as not statistically significantly different 
at the interim (abstract) analysis but statistically 
significantly different (in favour of paclitaxel) at the 
full analysis. 
Docetaxel
The BCIRG 001 trial30,31 reported overall survival 
and time to disease progression as interim data 
in an abstract and full data in a peer-reviewed 
publication. For overall survival, the risk ratio 
(adjusted for node status) was not statistically 
significant in the abstract30 but had reached 
statistical significance by the 5-year results reported 
in the full publication.31 For disease-free survival, 
the risk ratios (adjusted for node status) presented 
in both the abstract and the full 5-year publication 
were statistically significant. 
Direction of results reporting 
in abstract form 
Of the 11 trials that are not yet published in a 
full publication (see Table 9), only six reported 
overall survival or an outcome measuring time to 
disease progression. In the small sample of RCTs 
considered here, the statistical significance of 
results did not appear to affect the likelihood of 
full publication of data previously reported in a 
conference abstract. Indeed, four of the six trials 
included here reported statistically significant 
results. Similarly, statistical significance did 
not appear to influence the length of time to 
publication (or to the present date for unpublished 
studies). 
Ongoing trials
A number of trials in progress were identified in 
searches of the National Research Register and 
ClinicalTrials.gov, and these were assessed against 
the inclusion criteria for this review to see if they 
would be of relevance for any future update of this 
review. These trials are summarised in Appendix 
4; some may be related to trials included in this 
review.Health Technology Assessment 2008; Vol. 12: No. 32
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Chapter 5  
Discussion
T
he methodology for this short report was 
developed with a focus on relevance to 
the NICE appraisal process, i.e. assessment of 
published RCTs. As such, we identified publications 
from literature searches in the same way as for 
a systematic review, with additional searching 
of websites. Other work in this area has taken 
a different approach, by identifying trials from 
registers and following up for publications,24 or by 
following all abstracts from particular conferences 
to see when they became fully published.20,22,28 
Although these approaches are more 
comprehensive, time restrictions and the focus on 
the NICE appraisal process led us to adopt the 
different methodology discussed in Chapter 3. 
There were 41 publications of 18 RCTs that met 
the inclusion criteria for this review: three RCTs for 
docetaxel; two for paclitaxel; three for trastuzumab; 
two for gemcitabine; three for lapatinib; and five 
for bevacizumab.
Time to publication
The main focus of this review was the calculation 
of time from conference abstract to full publication 
for RCTs of paclitaxel, docetaxel, gemcitabine, 
trastuzumab, lapatinib and bevacizumab. 
For docetaxel, time to full publication varied from 
5 months for pathological response outcomes 
in the GEPARDUO trial,37 to 37 months for 
publication of interim survival in another trial.31 
Overall survival for the GEPARDUO trial was 
published in March 2006 as a conference abstract39 
but has not yet been published in full. The other 
trial had two conference abstracts32,34 and two 
full papers,33,35 but these did not report the same 
outcome measures and so could not be compared 
directly. 
The publication delay for paclitaxel trials tended 
to be longer than that for docetaxel trials, although 
it was difficult to compare the abstracts and full 
publications directly as both paclitaxel trials 
reported interim analyses in abstracts and final 
analyses in the full papers. For one trial41 the 
delay between the interim analysis appearing in 
an abstract and the final analysis being published 
in a full paper was 58 months, and there was a 
55-month delay in the other trial.46 One set of 
subgroup analyses was published more quickly (19 
months43), and another was still unpublished after 
15 months as of August 2007. 
For one of the trastuzumab trials there was only 
a 5-month delay between the interim analyses 
being published in a conference abstract and 
as a full paper,49 and a 7-month delay between 
the abstract and full publication of the 2-year 
follow-up analysis of patients who received a year 
of treatment. However, other trials have been 
published only as abstracts so far, with delays 
of 5–21 months as of August 2007. One of the 
gemcitabine RCTs identified by the literature 
searches has not yet been published in full, despite 
a delay of 38 months since the most recent abstract 
was presented at a conference.57  For the other 
identified gemcitabine trial, both a full paper and 
an abstract were identified, but the abstract did not 
present any efficacy data. 
The two most recent breast cancer drugs to be 
in the process of NICE appraisal are lapatinib 
and bevacizumab. Although one full paper was 
identified for a lapatinib trial,60 this only presented 
interim analysis. A more recent abstract of this 
trial61 and two of another trial62,63 had not been 
published in full as of August 2007. Only one full 
paper was presented for a bevacizumab trial,65 and 
the only abstract linked with this presented baseline 
data rather than any results. None of the other four 
bevacizumab trials have yet been published in full, 
with delays in publication of between 1570 and 3367 
months as of August 2007.
Overall, very few of the identified trials had 
both a conference abstract and a full publication 
that reported the same results. Mean time to 
publication for the three paclitaxel and docetaxel 
trials that had both an abstract and a full paper 
reporting the same outcome measures was 9 
months. Mean time without full publication 
for those trials that have only published as 
abstracts was 16.5 months to the end of August 
2007. The longest delays in publication were for 
trials investigating gemcitabine (38 months) or 
bevacizumab (33 months).Discussion
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Direction of effect
Overall survival and time to disease progression 
were of particular interest in this review as they are 
the measures most commonly used by NICE for 
analysis of an anti-cancer drug’s effectiveness. Only 
three trials reported the same outcome measures in 
both abstracts and a full publication, and only two 
sets of abstracts and publications (from the HERA 
trastuzumab trial) reported outcomes of overall 
survival and time to disease progression. For the 
HERA trial, the overall survival and time to disease 
progression results were consistent between the 
abstracts and corresponding full publications. 
Trials that published interim analysis in an 
abstract and final analysis in a full publication 
were examined separately from those discussed 
above. There were two paclitaxel trials and one 
docetaxel trial that fell into this category. One 
of the paclitaxel trials (INT0148) reported a 
positive effect on survival in both the abstract40 
and the full publication.41 The other paclitaxel 
trial (NSABP B-28) reported no significant 
difference at either the interim analysis45 or the 
final analysis.46 Disease-free survival was reported 
to be statistically better with paclitaxel by the time 
of the final analysis46 but not at the time of the 
interim analysis.45 The docetaxel trial reported 
statistically significant benefits of treatment with 
docetaxel in terms of overall survival and time to 
disease progression in both the abstract and full 
publication. The trials were therefore consistent in 
the direction of effect reported in the abstracts and 
full publications, with the exception of disease-free 
survival in the NSABP B-28 trial. 
Overall, it would appear that, when linkage of 
abstracts and full publications was possible, the 
results presented in the abstracts were in line with 
the results presented later in a full publication. It is 
important to note that this is based on observation 
of the data only (no statistical analysis was 
undertaken) and on a small sample of trials.
Limitations of the report
This short report was written within a tight 
timescale and as such there were a number of 
limitations that restricted the review at key stages. 
It was not possible to include studies beyond those 
drug combinations and patient groups appraised 
under the NICE STA programme. This restricted 
the available evidence and, although it allowed 
us to focus on the types of published evidence 
available to NICE under the STA programme, it 
resulted in a rather small sample size. No statistical 
analysis was performed because of the small sample 
size and the short time frame for this report.
Data extraction resources were focused on the 
key outcomes of overall survival and disease-free 
survival or time to progression. These were thought 
to be of most relevance to the NICE review process, 
but consideration of other outcomes could have 
yielded interesting data if resources had allowed. 
We calculated the mean time from abstract to 
full publication or to the time of writing if no 
full publication had occurred, i.e. the data were 
censored at the time of this analysis. This is a 
limitation of the project as mean times would 
be affected by the subsequent publication of full 
articles if the analysis were to be repeated at a later 
date. Health Technology Assessment 2008; Vol. 12: No. 32
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Chapter 6  
Conclusions
T
he aim of this short report was to identify the 
delay between conference abstracts and full 
publication of results from RCTs of new anti-cancer 
agents for breast cancer. The secondary aim was 
to identify any apparent biases in publication and 
reporting. 
Given that the searches identified 18 relevant RCTs 
it was rather surprising that only three of these had 
one or more full papers that reported the same 
outcome measures (and stage of analysis) as an 
earlier conference abstract. The trials that had fully 
published their results did so within a mean time 
frame of 9 months, which seems reasonable. Of the 
trials that have not yet published in full following 
earlier conference presentations, a longer mean 
delay of 16.5 months as of August 2007 was found. 
There did not appear to be any particular biases 
in terms of whether statistically significant results 
were more likely to be fully published than non-
significant ones. However, a limitation here is the 
small number of studies included in this report and 
the consequent lack of statistical analysis. 
This report has examined the data that is publicly 
available, of the kind that would be included in a 
systematic review of the literature carried out as 
part of the NICE appraisal process. Docetaxel, 
paclitaxel and trastuzumab all had at least one 
full publication reporting overall survival prior to 
NICE guidance being issued (although the overall 
survival data for the HERA trial appears to have 
been only interim analysis). For gemcitabine, 
no fully published data on overall survival was 
published prior to NICE guidance being produced. 
At the time of writing, NICE had not yet issued 
guidance on the use of bevacizumab or lapatinib. 
A further important source of evidence for the 
evidence review groups and NICE’s appraisal 
committee is the manufacturer’s submission. 
Such submissions usually contain unpublished 
data of trials that may be available publicly only 
as conference abstracts. Although the body of 
evidence reviewed by NICE therefore extends 
beyond that in the public domain, there is still the 
issue of whether or not such data is of the same 
quality as that published in peer-reviewed journals.
Research recommendations
Extension of this work to other anti-cancer  •	
drugs that have been through NICE’s MTA 
or earlier technology appraisal processes. 
With a larger sample size than that in the 
present report, investigation into the effect of 
publication delay on decision-making might be 
feasible. 
Investigation into the reasons for lengthy  •	
delays to full publication noted for some trials.
Investigation of publications appearing  •	
as ‘online early’, which may not appear in 
databases such as MEDLINE until a later date. 
Investigation of trials that publish as full  •	
papers but which do not have associated 
conference abstracts. Health Technology Assessment 2008; Vol. 12: No. 32
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Appendix 1  
MEDLINE search strategy for gemcitabine
Other interventions used the same search strategy, with replacement of drug names. The MEDLINE 
strategy was adapted for the other databases searched. 
Database and years 
searched
MEDLINE 1996–2007 Searched 31 July 2007
1 exp breast neoplasms/(74210)
2 (breast$adj4 (cancer$or tumo?r$or malignan$or carcinoma$or neoplasm$or oncolog$or 
sarcoma$or adenocarcinoma$)).ti,ab. (73935)
3 1 or 2 (90093)
4 randomized controlled trial.pt. (140941)
5 exp randomized controlled trials/(41205)
6 random allocation/(23124)
7 double blind method/(47144)
8 single blind method/(8464)
9 ((singl$or doubl$or trebl$or tripl$) adj3 (blind$or mask$)).ti,ab. (44877)
10 placebo$.ti,ab. (58048)
11 placebos/(8229)
12 random$.ti,ab. (248330)
13 or/4–12 (338240)
14 3 and 13 (7691)
15 (gemcitabine or gemcytabine or gemzar).mp. (4167)
16 14 and 15 (53)
17 limit 16 to humans (53)
18 limit 17 to yr=“2006 – 2007” (8)
19 from 18 keep 1–8 (8)
Search dates for other drugs
2002–2007 Capecitabine
2005–2007 Docetaxel
2006–2007 Paclitaxel
2000–2007 Vinorelbine
2000–2007 Trastuzumab
5 years pre-license – 2007 Bevacizumab
5 years pre-license – 2007 LapatinibHealth Technology Assessment 2008; Vol. 12: No. 32
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Appendix 2  
Data extractions
Docetaxel (Taxotere®; Sanofi-Aventis)
TABLE 10 Docetaxel: data extractions from STA (early breast cancer)
Publication details Number of participants Key outcomes Decisions by NICE
BCIRG 001
Martin et al., 200531
Month: June
Full publication: second 
interim analysis (median 
follow-up 55 months)
Trial identifier: BCIRG 001 
(Breast Cancer International 
Research Group)
Intervention: n = 745 TAC 
(docetaxel plus doxorubicin 
and cyclophosphamide) 
Comparator: n = 746 
FAC (fluorouracil 
plus doxorubicin and 
cyclophosphamide)
Overall survival: at 5 years 
87% of TAC vs 81% of 
FAC patients, with a 30% 
reduction in risk of death for 
TAC (hazard ratio 0.70, 95% 
CI 0.53–0.91, p < 0.008)
Time to disease progression: 
disease-free survival at 5 
years was 75% for TAC 
vs 68% for FAC patients, 
with a 28% reduction in the 
risk of relapse (hazard ratio 
0.72, 95% CI 0.59–0.88, 
p = 0.001) for the TAC 
group
Date: September 2006
Decision: docetaxel, 
when given concurrently 
with doxorubicin and 
cyclophosphamide (the TAC 
regimen) in accordance with 
its licensed indication, is 
recommended as an option 
for the treatment of women 
with early node-positive 
breast cancer following 
surgery.
Decision prior to this 
publication: no
Nabholtz et al., 200230
Month: May
Abstract (interim analysis)
Trial identifier: BCIRG 001 
Intervention: n = 745 TAC 
(docetaxel plus doxorubicin 
and cyclophosphamide) 
Comparator: n = 746 
FAC (fluorouracil 
plus doxorubicin and 
cyclophosphamide)
Patients were stratified by 
nodes (1–3, 4+)
Overall survival: RR TAC/
FAC (95% CI):
Adjusted for nodal status: 
0.76 (0.54–1.07), p = 0.11
Unadjusted: 0.75 (0.53–
1.06), p = 0.10
1–3 nodes: 0.46 (0.26–0.80), 
p = 0.006
4+ nodes: 1.08 (0.69–1.69), 
p = 0.75
Time to disease progression: 
disease-free survival RR 
TAC/FAC (95% CI):
Adjusted for nodal status: 
(first end point) 0.68 (0.54–
0.86), p = 0.0011
Unadjusted: 0.67 (0.53–
0.85), p = 0.0008
1–3 nodes: 0.50 (0.35–0.72), 
p = 0.0002
4+ nodes: 0.86 (0.63–1.17), 
p = 0.33
Date: September 2006
Decision: docetaxel, 
when given concurrently 
with doxorubicin and 
cyclophosphamide (the TAC 
regimen) in accordance with 
its licensed indication, is 
recommended as an option 
for the treatment of women 
with early node-positive 
breast cancer following 
surgery.
Decision prior to this 
publication: no
CI, confidence interval; RR, relative risk.Appendix 2
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TABLE 11 Docetaxel: identified fron new searches
Publication details Number of participants Key outcomes Decisions by NICE
NSABP B-27
Bear et al., 200635
Month: May
Full publication (first 
published report)
Trial identifier: NSABP 
B-27
n = 2411 randomised, 
n = 2404 with end point 
data
Group 1: n = 802 
doxorubicin and 
cyclophosphamide for 
four cycles followed by 
surgery
Group 2: n = 803 
doxorubicin and 
cyclophosphamide for 
four cycles plus docetaxel 
followed by surgery
Group 3: n = 799 
doxorubicin and 
cyclophosphamide 
followed by surgery 
followed by docetaxel 
Overall survival 
(reviewer reported as 
group population minus 
deaths): group 1: 645 
(80%), group 2: 647 
(81%); group 3: 628 
(79%). No statistically 
significant differences 
between groups
Addition of docetaxel 
had no significant 
impact
Time to disease 
progression: no 
statistically significant 
differences between 
groups for DFS
Improved DFS 
for preoperative 
docetaxel but not 
for postoperative in 
patients with clinical 
partial response after 
doxorubicin and 
cyclophosphamide 
(HR = 0.71, 95% CI 
0.55–0.91, p = 0.007)
Date: September 2006
Decision: docetaxel, when given 
concurrently with doxorubicin and 
cyclophosphamide (the TAC regimen) in 
accordance with its licensed indication, 
is recommended as an option for the 
treatment of women with early node-
positive breast cancer following surgery
Decision prior to this publication: no
Bear et al., 200434
Month: December
Abstract
Trial identifier: NSABP 
B-27
n = 2411 randomised, no 
breakdown 
Intervention: 
preoperative doxorubicin/
cyclophosphamide plus 
preoperative docetaxel 
Comparator 1: 
preoperative doxorubicin/
cyclophosphamide
Comparator 2: 
preoperative doxorubicin/
cyclophosphamide plus 
postoperative docetaxel
Overall survival: not 
reported
Time to disease 
progression: not 
reported
Results of tumour size 
and key characteristics 
Date: September 2006
Decision: docetaxel, when given 
concurrently with doxorubicin and 
cyclophosphamide (the TAC regimen) in 
accordance with its licensed indication, 
is recommended as an option for the 
treatment of women with early node-
positive breast cancer following surgery
Decision prior to this publication: no
Bear et al., 200333
Month: November
Full publication 
Trial identifier: NSABP 
B-27
Intervention: n = 805, 
preoperative doxorubicin/
cyclophosphamide plus 
docetaxel (group 2)
Comparators: n = 804, 
preoperative doxorubicin/
cyclophosphamide (group 
1); n = 802, preoperative 
doxorubicin/
cyclophosphamide plus 
postoperative docetaxel 
(group 3)
Overall survival: not 
reported
Time to disease 
progression: not 
reported
Reports on clinical and 
pathological complete 
and partial response 
rates and tumour size 
– follow-up data may 
report overall survival 
and DFS
Date: September 2006
Decision: docetaxel, when given 
concurrently with doxorubicin and 
cyclophosphamide (the TAC regimen) in 
accordance with its licensed indication, 
is recommended as an option for the 
treatment of women with early node-
positive breast cancer following surgery
Decision prior to this publication: noHealth Technology Assessment 2008; Vol. 12: No. 32
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Publication details Number of participants Key outcomes Decisions by NICE
Bear et al., 200132
Month: December
Abstract 
Trial identifier: NSABP 
B-27
n = 2500 randomised 
Intervention: 
preoperative doxorubicin/
cyclophosphamide (group 
1)
Comparators: 
preoperative doxorubicin/
cyclophosphamide 
followed by four cycles of 
preoperative docetaxel 
(group 2); preoperative 
doxorubicin/
cyclophosphamide 
followed by postoperative 
docetaxel (group 3)
All received tamoxifen
Overall survival: not 
reported
Time to disease 
progression: not 
reported
No data presented
Date: September 2006
Decision: docetaxel, when given 
concurrently with doxorubicin and 
cyclophosphamide (the TAC regimen) in 
accordance with its licensed indication, 
is recommended as an option for the 
treatment of women with early node-
positive breast cancer following surgery
Decision prior to this publication: no
GEPARDUO
von Minckwitz et al., 
200538
Month: April
Full publication (first 
phase of trial)
Trial identifier: 
GEPARDUO 
Intervention: n = 455 
randomised, doxorubicin 
plus docetaxel every 14 
days for four cycles with 
filgrastim support (group 
1) 
Comparator (detail): 
n = 458 randomised, 
doxorubicin plus 
cyclophosphamide every 
21 days followed by 
docetaxel every 21 days 
for four cycles (group 2)
Overall survival 
and time to disease 
progression: not 
reported
Disease progression 
or occurrence of new 
lesion detected in 14 in 
group 1 (3.2%) and 16 
in group 2 (3.7%)
Date: September 2006
Decision: docetaxel, when given 
concurrently with doxorubicin and 
cyclophosphamide (the TAC regimen) in 
accordance with its licensed indication, 
is recommended as an option for the 
treatment of women with early node-
positive breast cancer following surgery
Decision prior to this publication: no
Blohmer et al., 200639
Month: March
Abstract (first analysis 
of event-free and 
overall survival)
Trial identifier: 
GEPARDUO 
Intervention: n = 455 
randomised, doxorubicin 
plus docetaxel every 
14 days for four cycles 
with G-CSF (filgrastim) 
support (group 1)
Comparator: n = 458 
randomised, doxorubicin 
plus cyclophosphamide 
every 21 days followed by 
docetaxel every 21 days 
for four cycles (group 2)
Overall survival: 57 
deaths (group 1) vs 
48 deaths (group 2) 
at 5-year follow-up; 
5-year overall survival 
rates are estimated at 
81.0% (group 1) vs 
84.8% (group 2), log-
rank p = 0.24
5-year event-free 
survival rate was 65.0% 
(group 1) vs 66.1% 
(group 2), log-rank 
p = 0.66.
Time to disease 
progression: not 
reported
Date: September 2006
Decision: docetaxel, when given 
concurrently with doxorubicin and 
cyclophosphamide (the TAC regimen) in 
accordance with its licensed indication, 
is recommended as an option for the 
treatment of women with early node-
positive breast cancer following surgery
Decision prior to this publication: no
continued
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TABLE 11 Docetaxel: identified fron new searches (continued)
Publication details Number of participants Key outcomes Decisions by NICE
von Minckwitz et al., 
200236
Month: May
Abstract (second 
interim analysis, 
n = 395)
Trial identifier: 
GEPARDUO 
Intervention: n = 198 
randomised, 8-week 
schedule of doxorubicin 
(Adriamycin, Pharmacia 
SpA) plus docetaxel 
with G-CSF (filgrastim) 
support (group 1); 
tamoxifen given 
simultaneously
Comparator: n = 197 
randomised, sequential 
24-week schedule 
of doxorubicin plus 
cyclophosphamide 
followed by docetaxel 
(group 2); tamoxifen 
given simultaneously
Overall survival: not 
reported
Time to disease 
progression: not 
reported
At second interim 
analysis there was a 
large difference in the 
pathological complete 
response rate of 19.5% 
(99% CI 10.1–28.9)
Reviewer note: 
presuming it is in favour 
of ADOC, but not 
specified
Date: September 2006
Decision: docetaxel, when given 
concurrently with doxorubicin and 
cyclophosphamide (the TAC regimen) in 
accordance with its licensed indication, 
is recommended as an option for the 
treatment of women with early node-
positive breast cancer following surgery
Decision prior to this publication: no
Jackisch et al., 200237
Month: October
Full paper (second 
interim analysis)
Trial identifier: 
GEPARDUO 
913 enrolled in study 
but for this interim 
analysis results on 395 
randomised
Intervention: n = 191, 
four cycles of doxorubicin 
+ docetaxel ± tamoxifen 
(group 1) 
Comparator: n = 178, 
sequential doxorubicin/
cyclophosphamide 
followed by docetaxel 
over 24 weeks (group 2)
Overall survival: not 
reported
Time to disease 
progression: not 
reported
Results on pathological 
remission and toxicity 
Date: September 2006
Decision: docetaxel, when given 
concurrently with doxorubicin and 
cyclophosphamide (the TAC regimen) in 
accordance with its licensed indication, 
is recommended as an option for the 
treatment of women with early node-
positive breast cancer following surgery
Decision prior to this publication: no
ADOC, adriamycin + docetaxel; CI, confidence interval; DFS, disease-free survival; G-CSF, granulocyte-colony stimulating 
factor; HR, hazard ratio.Health Technology Assessment 2008; Vol. 12: No. 32
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Paclitaxel (Taxol®, Bristol-Myers Squibb; Paxene®, Norton Healthcare)
TABLE 12 Paclitaxel: from STA (early breast cancer)
Publication details Number of participants Key outcomes Decisions by NICE
INT 0148 (intergroup trial) and CALGB-9344
Henderson et al., 200341
Month: March
Full publication 
Trial identifier: INT 0148 
(intergroup trial) and 
CALGB-9344
n = 3170 randomised; n = 3121 
received treatment
First randomisation to one of 
three doses of doxorubicin 
and cyclophosphamide, second 
randomisation to receive or not 
receive paclitaxel
Intervention: total n = 1590, 
cyclophosphamide plus escalating 
dose of doxorubicin for four cycles 
(n = 1060, 60 mg/m2; n = 1053, 75 
mg/m2; n = 1057, 90 mg/m2) followed 
by four cycles of paclitaxel (group 1)
Comparator: total n = 1580, 
cyclophosphamide and escalating 
dose of doxorubicin for four cycles 
(n = 1060, 60mg/m2; n = 1053, 75mg/
m2; n = 1057, 90mg/m2) (group 2)
Overall survival (±SE): 77% 
(±1) for group 2 vs 80% 
(±1) for group 1 at 5 years; 
68% (±2) for group 2 vs 
74% (±2) for group 1 at 7 
years
Time to disease 
progression: hazard 
reductions from adding 
paclitaxel were 17% for 
recurrence (p = 0.0023 
adjusted, p = 0.0011 
unadjusted) and 18% for 
death (p = 0.0064 adjusted, 
p = 0.0098 unadjusted)
At 5 years, disease-free 
survival (±SE) was 65% (±1) 
for group 2 vs 70% (±1) for 
group 1; at 7 years, disease-
free survival (±SE) was 58% 
(±2) for group 2 vs 64% 
(±2) for group 1
Date: September 2006
Decision: paclitaxel, 
within its licensed 
indication, is not 
recommended for the 
adjuvant treatment 
of women with early 
node-positive breast 
cancer
Decision prior to this 
publication: no
Henderson et al., 199840
Month: May
Abstract (first interim 
analysis)
Trial identifier: INT 0148/
CALGB-9344
n = 3170 randomised 
First randomisation to one of 
three doses of doxorubicin 
and cyclophosphamide, second 
randomisation to receive or not 
receive paclitaxel
Intervention: cyclophosphamide plus 
doxorubicin – 60, 75 or 90 mg/m2 – 
followed by four cycles of paclitaxel 
(group 1)
Comparator: cyclophosphamide plus 
doxorubicin – 60, 75 or 90 mg/m2 
(group 2)
Overall survival: no 
differences in overall 
survival related to dose 
of doxorubicin; paclitaxel 
reduced death rate by 26%
Time to disease 
progression: not reported
Paclitaxel reduced 
recurrence rate by 22%
Addition of paclitaxel 
significantly improved 
overall survival and DFS; no 
p-values, etc. given
Toxicity also reported
Date: September 2006
Decision: paclitaxel, 
within its licensed 
indication, is not 
recommended for the 
adjuvant treatment 
of women with early 
node-positive breast 
cancer
Decision prior to this 
publication: no
continuedAppendix 2
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Publication details Number of participants Key outcomes Decisions by NICE
Sartor et al., 200342
Month: June
Abstract
Trial identifier: 
CALGB-9344 (INT 0148) 
Subgroup analysis
n = 1111, data for n = 996
Intervention: four cycles of 
doxorubicin/Cytoxan (Neosar; 
cyclophosphamide) – 60, 75 or 90 
mg/m2 – followed by four cycles of 
paclitaxel 
Comparator: four cycles 
of doxorubicin/Cytoxan 
(cyclophosphamide) – 60, 75 or 90 
mg/m2
Overall survival: not 
reported
Time to disease 
progression: not reported
Data for radiotherapy 
delivery only
Date: September 2006
Decision: paclitaxel, 
within its licensed 
indication, is not 
recommended for the 
adjuvant treatment 
of women with early 
node-positive breast 
cancer
Decision prior to this 
publication: no
Hayes et al., 200644
Month: June
Abstract
Trial identifier: 
CALGB-9344
Subgroup analysis
n ~ 2800, two sets of 750 patients 
randomly selected – set 1 to test 
hypothesis, set 2 for validation
Intervention: four cycles of 
doxorubicin/cyclophosphamide – 60, 
75 or 90 mg/m2 – followed by four 
cycles of paclitaxel
Comparator: four cycles of 
doxorubicin/cyclophosphamide – 60, 
75 or 90 mg/m2
Overall survival: not 
reported, refers to original 
publication
Time to disease 
progression: not reported
Only for both sets 
combined, significant 
differences in 5-year DFS 
rates (95% CI) for paclitaxel 
vs no paclitaxel by HER2 
and estrogen receptor (ER)
Benefits of adding paclitaxel 
greater for HER2+ tumours 
with ER+
Date: September 2006
Decision: paclitaxel, 
within its licensed 
indication, is not 
recommended for the 
adjuvant treatment 
of women with early 
node-positive breast 
cancer
Decision prior to this 
publication: no
Sartor et al., 200543
Month: January 
Full publication 
Trial identifier: INT 0148/
CALGB-9344 
Subgroup analysis
Subgroups: mastectomy patients 
treated with radiotherapy (RT), 
mastectomy patients not treated 
with RT and patients with breast-
conserving therapy and RT; also 
subgroups by number of nodes 
Intervention AC-T: four cycles of 
doxorubicin/cyclophosphamide – 60, 
75 or 90 mg/m2 – followed by four 
cycles of paclitaxel
Comparator: doxorubicin/
cyclophosphamide – 60, 75 or 90 mg/
m2
Overall survival: not 
reported
Time to disease 
progression: not reported
Results on 5-year cumulative 
incidence of isolated 
locoregional recurrence 
Date: September 2006
Decision: paclitaxel, 
within its licensed 
indication, is not 
recommended for the 
adjuvant treatment 
of women with early 
node-positive breast 
cancer
Decision prior to this 
publication: no
TABLE 12 Paclitaxel: from STA (early breast cancer) (continued)Health Technology Assessment 2008; Vol. 12: No. 32
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Publication details Number of participants Key outcomes Decisions by NICE
NSABP B-28
Mamounas et al., 200546
Month: June
Full publication 
Trial identifier: NSABP 
B-28 (national surgical 
adjuvant breast and bowel 
cancer project)
Intervention: n = 1531, doxorubicin 
plus cyclophosphamide plus paclitaxel 
(group 1)
Comparator: n = 1529, doxorubicin 
plus cyclophosphamide (group 2)
Overall survival: a non-
statistically significant 7% 
reduction in death rate with 
addition of paclitaxel (RR 
0.93, 95% CI 0.78–1.12, 
p = 0.46); 5-year overall 
survival rate 85% (±2%) 
for both groups
Time to disease 
progression: addition of 
paclitaxel significantly 
reduced the risk of a 
DFS event by 17% (RR 
0.83, 95% CI 0.72–0.95, 
p = 0.006); 5-year DFS 76% 
(±2%) for group 1 vs 72% 
(±2%) for group 2
Date: September 2006
Decision: paclitaxel, 
within its licensed 
indication, is not 
recommended for the 
adjuvant treatment 
of women with early 
node-positive breast 
cancer
Decision prior to this 
publication: no
Mamounas et al., 200347
Month: June
Abstract
Trial identifier: NSABP 
B-28
Randomised: n = 3060
Intervention: doxorubicin plus 
cyclophosphamide plus paclitaxel 
Comparator: doxorubicin plus 
cyclophosphamide
Overall survival: not 
reported
Time to disease 
progression: not reported
(As of 18 December 2002, 
472 deaths and 827 events 
reported)
Date: September 2006
Decision: paclitaxel, 
within its licensed 
indication, is not 
recommended for the 
adjuvant treatment 
of women with early 
node-positive breast 
cancer
Decision prior to this 
publication: no
Mamounas 200045
Month: November
Abstract 
Trial identifier: NSABP 
B-28 (interim analysis)
Randomised: n = 3060 
Intervention: four cycles of 
doxorubicin and cyclophosphamide 
followed by four cycles of paclitaxel 
(group 1)
Comparator: four cycles of 
doxorubicin and cyclophosphamide 
(group 2)
Overall survival:  no 
statistically significant 
difference between arms for 
survival or death (deaths: 
113 group 2/136 group 
1; relative risk 1.0, 95% 
CI 0.78–1.27, p = 0.98). 
Estimated survival at 36 
months is 92% group 2 and 
90% group 1
Time to disease 
progression: no statistically 
significant difference 
between arms for DFS 
(events: 282 group 2/269 
group 1; relative risk 
0.93, 95% CI 0.78–1.10, 
p = 0.38). Estimated DFS at 
36 months is 81% for both 
arms
Date: September 2006
Decision: paclitaxel, 
within its licensed 
indication, is not 
recommended for the 
adjuvant treatment 
of women with early 
node-positive breast 
cancer
Decision prior to this 
publication: no
CI, confidence interval; DFS, disease-free survival.
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Trastuzumab 
TABLE 13 Trastuzumab: from STA (early breast cancer)
Publication details Number of participants Key outcomes Decisions by NICE
HERA
Piccart-Gebhart et al., 
200549
Month: October
Full publication (interim 
analysis – median 1-year 
follow-up)
Trial identifier: HERA 
(BIG 01–01)
Intervention group 1: n = 1694, 
2 years of trastuzumab – not 
reported here
Intervention group 2: n = 1694, 
1 year of trastuzumab 
Comparator: n = 1693, 
observation 
Overall survival: 96.0% 
trastuzumab group vs 95.1% 
observation group; hazard 
ratio 0.76 (95% CI 0.47–1.23, 
p = 0.26)
Time to disease progression: 
DFS 127 events in the 
trastuzumab group vs 220 
events in the observation 
group; hazard ratio for risk of 
an event in trastuzumab group 
vs observation group 0.54 
(95% CI 0.43–0.67, log-rank 
test p < 0.0001) – equivalent 
to DFS of 8.4% points at 2 
years (95% CI 2.1–14.8)
Hazard ratio for time to distant 
recurrence for trastuzumab 
vs observation 0.49 (95% 
CI 0.38–0.63, p < 0.0001) – 
reduced rate of recurrence 
approximately 50% higher for 
traztuzumab
Date: August 2006
Decision: trastuzumab 
is recommended as a 
treatment option for 
women with early-stage 
HER2-positive breast 
cancer following surgery, 
chemotherapy (neoadjuvant 
or adjuvant) and 
radiotherapy (if applicable)
Decision prior to this 
publication: no
The HERA study team, 
200548
Month: May 
Abstract (interim 
analysis)
Trial identifier: HERA 
(BIG 01–01)
n = 5090 enrolled
Intervention group 1: n = 1694, 
1 year of trastuzumab 
Intervention group 2: 
n = not reported, 2 years of 
trastuzumab 
Comparator: n = 1693, 
observation 
Overall survival: at 2 years 
96.0% (1 year of trastuzumab) 
vs 95.1% (observation); 
hazard ratio 0.76 (95% CI 
0.47–1.23, p = 0.26). Events 
29 (1 year of trastuzumab) vs 
37 (observation)
Time to disease progression: 
DFS at 2 years 85.8% (1 year 
of trastuzumab) vs 77.4% 
(observation); hazard ratio 
0.54 (95% CI 0.43–0.67, 
p < 0.0001). Events 127 (1 
year of trastuzumab) vs 220 
(observation)
2-year trastuzumab arm 
improved DFS compared with 
observation (p < 0.0001)
DFS at 2 years 89.7% (1 year 
of trastuzumab) vs 81.8% 
(observation); hazard ratio 
0.51 (95% CI 0.40–0.66, 
p < 0.0001). Events 98 (1 
year of trastuzumab) vs 179 
(observation)
Date: August 2006
Decision: trastuzumab 
is recommended as a 
treatment option for 
women with early-stage 
HER2-positive breast 
cancer following surgery, 
chemotherapy (neoadjuvant 
or adjuvant) and 
radiotherapy (if applicable)
Decision prior to this 
publication: noHealth Technology Assessment 2008; Vol. 12: No. 32
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Publication details Number of participants Key outcomes Decisions by NICE
Smith, 200650
Month: June
Abstract
Trial identifier: HERA
n = 5102 enrolled
Intervention group 1: n = 1703, 
1 year of trastuzumab 
Intervention group 2: 2 years of 
trastuzumab, not reported here
Comparator: n = 1698, 
observation 
2-year median follow-up 
time of 1 year of treatment – 
overall survival: hazard ratio 
0.59 (95% CI 0.43–0.82, 
p = 0.0016); events 59 vs 90; 2 
year 96.9% vs 93.6%
2-year median follow-up 
time of 1 year of treatment 
– disease progression: DFS 
hazard ratio 0.60 (95% CI 
0.50–0.71, p = 0.0001); events 
218 vs 321; 2 year 86.1% vs 
78.0%
TTR: hazard ratio 0.57 (95% 
CI 0.48–0.69, p = 0.0001); 
events 198 vs 305; 2 year 
87.3% vs 79.1%
TTDR: hazard ratio 0.56 (95% 
CI 0.46–0.68, p = 0.0001); 
events 160 vs 255; 2 year 
90.1% vs 82.2%
Date: August 2006
Decision: trastuzumab 
is recommended as a 
treatment option for 
women with early-stage 
HER2-positive breast 
cancer following surgery, 
chemotherapy (neoadjuvant 
or adjuvant) and 
radiotherapy (if applicable)
Decision prior to this 
publication: yes
Smith et al., 200751
Month: January
Full publication
Trial identifier: HERA
Intervention: n = 1703, 
trastuzumab for 1 year
Comparator: n = 1698, 
observation alone
2 year follow-up time of 1 year 
of treatment
Overall survival: 59 (3%) 
versus 90 (5%) deaths in 
the trastuzumab group and 
observation group respectively. 
The unadjusted hazard ratio 
for the risk of death in the 
trastuzumab group compared 
with the observation group 
was 0.66 (95% CI 0.47–
0.91, p = 0.0115), which 
corresponds to an absolute 
overall survival benefit of 2.7% 
(92.4% vs 89.7%) at 3 years
Time to disease progression: 
218 DFS events were reported 
with trastuzumab compared 
with 321 for observation. 
The unadjusted hazard ratio 
for the risk of an event in the 
trastuzumab group compared 
with the observation group 
was 0.64 (95% CI 0.54–
0.76, p < 0.0001), which 
corresponds to an absolute 
DFS benefit of 6.3% (80.6% 
vs 74.3%)
Date: August 2006
Decision: trastuzumab 
is recommended as a 
treatment option for 
women with early-stage 
HER2-positive breast 
cancer following surgery, 
chemotherapy (neoadjuvant 
or adjuvant) and 
radiotherapy (if applicable)
Decision prior to this 
publication: yes
continued
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Publication details Number of participants Key outcomes Decisions by NICE
BCIRG 006
Slamon et al., 200552
Month: December
Abstract (first interim 
analysis)
Trial identifier: BCIRG 
006
Intervention: n = 1073, 
doxorubicin and 
cyclophosphamide plus 
docetaxel 
Comparator 1: n = 1074, 
doxorubicin and 
cyclophosphamide plus 
docetaxel plus trastuzumab 
(AC-TH)
Comparator 2: n = 1075, 
docetaxel plus carboplatin plus 
trastuzumab (TCH)
Overall survival: not reported 
Time to disease progression: 
DFS hazard ratio 0.49 
with comparator 1 
(p = 0.00000048) and 
0.61 with comparator 2 
(p = 0.00015) compared with 
intervention. No significant 
difference between the two 
trastuzumab-containing arms
Date: August 2006
Decision: trastuzumab 
is recommended as a 
treatment option for 
women with early-stage 
HER2-positive breast 
cancer following surgery, 
chemotherapy (neoadjuvant 
or adjuvant) and 
radiotherapy (if applicable).
Decision prior to this 
publication: no
Slamon 200753
Month: April
Abstract (second interim 
analysis – taken from PP)
Trial identifier: BCIRG 
006
Intervention: n = 1073, 
doxorubicin and 
cyclophosphamide plus 
docetaxel (AC-T)
Comparator 1: n = 1074, 
doxorubicin and 
cyclophosphamide plus 
docetaxel plus trastuzumab 
(AC-TH)
Comparator 2: n = 1075, 
docetaxel plus carboplatin plus 
trastuzumab (TCH)
Overall survival at year 4: 
intervention 86%, comparator 
2 91%, comparator 1 92%. 
Hazard ratio 0.59 (95% CI 
0.42–0.85) with comparator 1 
(p = 0.004) and 0.66 (95% CI 
0.47–0.93) with comparator 
2 (p = 0.017), compared with 
intervention
Time to disease progression: 
DFS hazard ratio 0.61 (95% CI 
0.48–0.76) with comparator 1 
(p < 0.0001) and 0.67 (95% CI 
0.54–0.83) with comparator 
2 (p = 0.0003) compared 
with intervention. Absolute 
DFS benefits (from year 2 
to year 4): comparator 1 vs 
intervention 6%; comparator 
2 vs intervention 5%
Disease free at year 4: 
intervention 77%, comparator 
2 82%, comparator 1 83%
Date: August 2006
Decision: trastuzumab 
is recommended as a 
treatment option for 
women with early-stage 
HER2-positive breast 
cancer following surgery, 
chemotherapy (neoadjuvant 
or adjuvant) and 
radiotherapy (if applicable)
Decision prior to this 
publication: yes
CI, confidence interval; DFS, disease-free survival; PP , PowerPoint presentation; TTDR, time to distant recurrence; TTR, 
time to recurrence.
TABLE 13 Trastuzumab: from STA (early breast cancer) (continued)
TABLE 14 Trastuzumab: new studies
Publication details Number of participants Key outcomes Decisions by NICE
Spielmann et al., 200654
Month: June
Abstract
Trial identifier: PACS 04 
(clinical trial number: FRE-
FNCLCC-PACS-04/0005)
First randomisation: 
intervention: n = 1518, 
5-fluorouracil–epirubicin–
cyclophosphamide (FEC100) vs 
n = 1492, epirubicin–docetaxel 
(ET75) 
Followed by second 
randomisation of HER2-positive 
patients to two groups: n = 259 
trastuzumab 1 year vs n = 241 
observation only 
Overall survival: not 
reported
Time to disease 
progression: not reported
Results for toxicity and 
safety only for first 
randomisation
Date: August 2006
Decision: trastuzumab is 
recommended as a treatment 
option for women with early-
stage HER2-positive breast 
cancer following surgery, 
chemotherapy (neoadjuvant or 
adjuvant) and radiotherapy (if 
applicable)
Decision prior to this 
publication: yesHealth Technology Assessment 2008; Vol. 12: No. 32
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Gemcitabine (Gemzar®, Lilly)
TABLE 15 Gemcitabine: from STA
Publication details Number of participants Key outcomes Decisions by NICE
JHQG
O’Shaughnessy et al., 
200355
Month: June
Abstract
Trial identifier: B9E-MC-
JHQG, referred to as 
JHQG
Intervention: n = 267, 
gemcitabine plus paclitaxel 
(group 1)
Comparator: n = 262, paclitaxel 
alone (group 2)
Overall survival: reports 
insufficient events for overall 
survival, which will be 
determined at final analysis
Median time to disease 
progression: 5.4 months 
(95% CI 4.6–6.1) group 1 
vs 3.5 months (95% CI 2.9–
4.0) group 2 (p = 0.0013) 
Hazard ratio 0.734 (95% CI 
0.607–0.889, p = 0.0015) 
with an increased probability 
of approximately 50% for 
group 1 of being progression 
free at 6 months. PFS was 
significantly better with 
group 1 (p = 0.0021)
Date: Jan 2007
Decision: gemcitabine plus 
paclitaxel is recommended 
as a treatment option for 
women with metastatic breast 
cancer, but only in cases when 
docetaxel monotherapy or 
docetaxel plus capecitabine 
are also appropriate
Decision prior to this 
publication: no
Albain et al., 200456
Month: July
Abstract
Trial identifier: B9E-MC-
JHQG, referred to as 
JHQG
Intervention: n = 267, 
gemcitabine plus paclitaxel 
(group 1)
Comparator: n = 262, paclitaxel 
alone (group 2)
Median overall survival: 
group 1 18.5 months (95% 
CI 16.5–21.2) vs group 
2 15.8 months (95% CI 
14.4–17.4). Hazard ratio 
0.775 (95% CI 0.627–0.959) 
in favour of group 1 
(p = 0.018). 1-year survival 
was group 1 70.7% (95% CI 
65.1–76.3) versus group 2 
60.9% (95% CI 54.8–66.9) 
(p = 0.019)
Time to disease progression: 
as reported above
Date: Jan 2007
Decision: gemcitabine plus 
paclitaxel is recommended 
as a treatment option for 
women with metastatic breast 
cancer, but only in cases when 
docetaxel monotherapy or 
docetaxel plus capecitabine 
are also appropriate
Decision prior to this 
publication: no
Moinpour et al., 200457
Month: July
Abstract
Trial identifier: B9E-MC-
JHQG, referred to as 
JHQG
Intervention: n = 267, 
gemcitabine plus paclitaxel
Comparator: n = 262, paclitaxel 
alone 
Overall survival: as reported 
in above
Time to disease progression: 
as reported in above
This abstract reports pain 
and QoL
Date: Jan 2007
Decision: gemcitabine plus 
paclitaxel is recommended 
as a treatment option for 
women with metastatic breast 
cancer, but only in cases when 
docetaxel monotherapy or 
docetaxel plus capecitabine 
are also appropriate
Decision prior to this 
publication: no
CI, confidence interval; PFS, progression-free survival; QoL, quality of life.Appendix 2
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TABLE 16 Gemcitabine: from new searches
Publication details Number of participants Key outcomes Decisions by NICE
B9E-MC-S197
Khoo et al., 200458
Month: July
Abstract
Trial identifier: B9E-
MC-S197
n = 210 enrolled, n = 204 
for response assessment 
(breakdown in table not 
abstract)
Intervention 1: n = 72, 
gemcitabine 1250 mg/m2 
days 1 and 8 plus paclitaxel 
175 mg/m2 as 3-hour infusion 
day 1 
Intervention 2: n = 67, 
gemcitabine 1000 mg/m2 days 
1 and 8 plus paclitaxel 100 
mg/m2 as 1-hour infusion days 
1 and 8 
Intervention 3: n = 65, 
gemcitabine 1000 mg/m2 days 
1 and 8 plus docetaxel 40 mg/
m2 as 1-hour infusion days 1 
and 8 
Overall survival: not 
reported
Time to disease 
progression: not reported
Efficacy outcomes were 
similar in the three arms – 
no data reported. Results 
for toxicity, side-effects and 
adverse events
Date: Jan 2007
Decision: gemcitabine plus 
paclitaxel is recommended 
as a treatment option for 
women with metastatic breast 
cancer, but only in cases when 
docetaxel monotherapy or 
docetaxel plus capecitabine 
are also appropriate
Decision prior to this 
publication: no
Khoo et al., 200659
Month: August
Full publication 
Trial identifier: B9E-
MC-S197
n = 210 randomised, n = 204 
for response assessment
Intervention 1: n = 73 (72) 
group 1, gemcitabine 1250 
mg/m2 days 1 and 8 plus 
paclitaxel 175 mg/m2 as 
3-hour infusion day 1 
Intervention 2: n = 69 (67) 
group 2, gemcitabine 1000 
mg/m2 days 1 and 8 plus 
paclitaxel 100 mg/m2 as 
1-hour infusion days 1 and 8 
Comparator: n = 68 (65) 
group 3, gemcitabine 1000 
mg/m2 days 1 and 8 plus 
docetaxel 40 mg/m2 as 1-hour 
infusion days 1 and 8 
Overall survival: not 
reported
Time to disease 
progression: group1 7.5 
months, group 2 7.0 
months, group 3 7.4 
months 
Hazard ratio estimate 
(95% CI): group 1 vs group 
2, 0.96 (0.65–1.42); group 
1 vs group 3, 0.97 (0.65–
1.44); group 2 vs group 3, 
1.01 (0.68–1.51)
Date: Jan 2007
Decision: gemcitabine plus 
paclitaxel is recommended 
as a treatment option for 
women with metastatic breast 
cancer, but only in cases when 
docetaxel monotherapy or 
docetaxel plus capecitabine 
are also appropriate
Decision prior to this 
publication: no
CI, confidence interval.Health Technology Assessment 2008; Vol. 12: No. 32
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Lapatinib (Tykerb®, GlaxoSmithKline)
TABLE 17 Lapatinib: no previous NICE guidance
Publication details Number of participants Key outcomes Decisions by NICE
NCT00078572
Geyer et al., 200660
Month: December
Full publication (interim 
analysis – early reporting on 
the basis of superiority of 
combination treatment)
Trial identifier: clinical trial 
number: NCT00078572
Intervention: n = 163, 
lapatinib plus capecitabine
Comparator: n = 161, 
capecitabine
Overall survival: not reported 
per se but 22% deaths for 
dual therapy and 22% deaths 
for monotherapy; hazard 
ratio 0.92 (95% CI 0.58–
1.46, p = 0.72)
Median time to disease 
progression: 8.4 months, 49 
disease progression events 
(dual therapy) vs 4.4 months, 
72 events (monotherapy); 
hazard ratio 0.49 (95% CI 
0.34–0.71, p < 0.001)
Date: NA
Decision: none
Decision prior to this 
publication: no
Geyer et al., 200761
Month: June
Abstract (updated efficacy 
analysis and interim 
correlative analysis of gene 
expression levels)
Trial identifier: EGF100151
Intervention: lapatinib plus 
capecitabine (group 1) 
Comparator: capecitabine 
(group 2)
Data available for 
n = 217/399 so far
Overall survival: group 1 
vs group 2 hazard ratio 
0.78 (95% CI 0.55–1.12, 
p = 0.177)
Time to disease progression:
TTP: group 1 27 weeks vs 
group 2 19 weeks; hazard 
ratio 0.57 (95% CI 0.43–
0.77, p = 0.00013)
ORR: group 1 24% vs group 
2 14%; odds ratio 1.90 (95% 
CI 1.00–1.34, p = 0.017)
Progression in CNS 
metastases: group 1 2% vs 
group 2 11% (p = 0.0445)
Date: NA
Decision: none
Decision prior to this 
publication: no
Sherrill
Sherrill et al., 200762
Month: June
Abstract
Intervention: n = 198 (ITT), 
lapatinib plus capecitabine 
(group 1)
Comparator: n = 201 (ITT), 
capecitabine (group 2)
Overall median survival: 
67 weeks (based on 2006 
data); 7 weeks’ difference 
in quality-adjusted 
survival favouring group 1 
(p=0.0013).Time to disease 
progression: not reported
Date: NA
Decision: none
Decision prior to this 
publication: no
continuedAppendix 2
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TABLE 17 Lapatinib: no previous NICE guidance (continued)
Publication details Number of participants Key outcomes Decisions by NICE
Cameron
Cameron et al., 200663
Month: December
Abstract (interim analysis)
Intervention: lapatinib plus 
capecitabine (group 1)
Comparator: capecitabine 
alone (group 2)
n = 321 to date, randomised 
1:1 – no breakdown
Overall survival: not 
reported
Median PFS: group 1 36.9 
weeks vs group 2 17.9 
weeks; hazard ratio 0.48 
(95% CI 0.33–0.70, log-rank 
p = 0.000045)
Median time to disease 
progression: group 1 36.9 
weeks vs group 2 19.7 
weeks; hazard ratio 0.51 
(95% CI 0.35–0.74, log-rank 
p = 0.00016)
Date: NA
Decision: none
Decision prior to this 
publication: no
CI, confidence interval; CNS, central nervous system; ITT, intention to treat; NA, not applicable; ORR, overall response 
rate; PFS, progression-free survival; TTP , time to progression.Health Technology Assessment 2008; Vol. 12: No. 32
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Bevacizumab (Avastin®, Roche)
TABLE 18 Bevacizumab: no previous NICE guidance
Publication details Number of participants Key outcomes Decisions by NICE
Miller
Miller et al., 200565
Month: February
Full publication 
Intervention: n = 232, 
capecitabine with 
bevacizumab (group 1)
Comparator: n = 230, 
capecitabine (group 2)
Median overall survival: 15.1 
months group 1 vs 14.5 months 
group 2 – comparable in both 
treatment groups
Time to disease progression: 
median PFS: 4.86 months group 
1 vs 4.17 months group 2; hazard 
ratio 0.98
No NICE guidance at 
present
Decision prior to this 
publication: no
Miller et al., 200264
Month: December
Abstract
Intervention: capecitabine 
with bevacizumab (group 1)
Comparator: capecitabine 
(group 2)
n = 462 randomised, no 
breakdown
Overall survival: not reported
Time to disease progression: not 
reported
Results on baseline data only. Full 
analysis due September 2002
No NICE guidance at 
present
Decision prior to this 
publication: no
Overmoyer
Overmoyer et al., 200467
Month: December
Abstract
Intervention: n = 20, 
bevacizumab and docetaxel 
(group 1)
Comparator: n = 18, 
docetaxel (group 2)
Overall survival: not reported
Time to disease progression: not 
reported
Results on tumour size, toxicity, 
IAUC and serum VCAM-1 levels
No NICE guidance at 
present
Decision prior to this 
publication: no
Overmoyer et al., 200466
Month: July
Abstract
Intervention: bevacizumab 
and docetaxel (group 1)
Comparator: docetaxel 
(group 2)
n = 33 randomised to date, 
no breakdown
Overall survival: not reported
Time to disease progression: not 
reported
Results on tumour size and 
toxicity 
No NICE guidance at 
present
Decision prior to this 
publication: no
E2100
Miller et al., 200568
Month: December
Abstract
Trial identifier: E2100 
(Eastern Cooperative 
Oncology Group, ECOG)
Intervention: paclitaxel with 
bevacizumab (group 1)
Comparator: paclitaxel 
(group 2)
n = 722 enrolled, no 
breakdown
Overall survival: data are 
immature – early follow-up 
suggests that group 1 has 
improved overall survival (hazard 
ratio 0.674, p = 0.01)
Time to disease progression: 
group 1 has significantly prolonged 
PFS (10.97 months vs 6.11 
months; hazard ratio 0.498, 
p < 0.001)
Group 1 significantly increased 
response rates in all patients 
(28.2% vs 14.2%; p < 0.0001) 
and in the subset of patients with 
measurable disease (34.3% vs 
16.4%; p < 0.0001)
No NICE guidance at 
present
Decision prior to this 
publication: no 
continuedAppendix 2
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Publication details Number of participants Key outcomes Decisions by NICE
Wagner et al., 200669
Month: December
Abstract
Trial identifier: Eastern 
Co-operative Oncology 
Group (ECOG) study 
E2100
Intervention: n = 368, 
paclitaxel with bevacizumab 
(group 1)
Comparator: n = 354, 
paclitaxel (group 2)
Overall survival: not reported
Time to disease progression: not 
reported
Results on self-reported 
symptom burden and HRQoL – 
improvement in clinical outcomes 
stated but data not reported
No NICE guidance at 
present
Decision prior to this 
publication: no
Lyons
Lyons et al., 200670
Month: June
Abstract
Intervention: n = 24, 
bevacizumab and docetaxel 
(group 1)
Comparator: n = 25, 
docetaxel (group 2)
Overall survival: not reported
Time to disease progression: not 
reported
Phase II study – results on tumour 
size, toxicity, wound healing and 
changes in LVEF
No NICE guidance at 
present
Decision prior to this 
publication: no
Burstein
Burstein et al., 200571
Month: December
Abstract (interim 
analysis)
Intervention: (n = 34) 
cyclophosphamide 
and methotrexate plus 
bevacizumab
Comparator: (n = 21) 
cyclophosphamide and 
methotrexate 
(Information in parentheses 
from internet)
At the time of this 
publication, n = 41 enrolled 
with accrual of a further 13 
to dual therapy continuing
Overall survival: not reported
Time to disease progression: not 
reported
No NICE guidance at 
present
Decision prior to this 
publication: no
HRQoL, health-related quality of life; IAUC, incremental area under the curve; LVEF, left ventricular ejection fraction; PS, 
progression-free survival; VCAM-1, vascular cell adhesion molecule-1.
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Appendix 3  
Flow chart of systematic review process
Identified on searching
(after duplicates removed)
n = 1556
Included references n = 41,
of which n = 18 RCTs
Excluded
n = 1365
Excluded
n = 121
Excluded
n = 30
References for retrieval
n = 191
Papers inspected
n = 71
Titles and abstracts
inspected using protocol
screening criteria
PROTOCOL
AMENDMENT, LIMITING
TO NICE STA DRUGSHealth Technology Assessment 2008; Vol. 12: No. 32
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Appendix 4  
Details of related ongoing trials
Paclitaxel
NCT00041119. A trial comparing 
cyclophosphamide and doxorubicin (CA) (four 
versus six cycles) versus paclitaxel (four versus six 
cycles) as adjuvant therapy for breast cancer in 
women with 0–3 positive auxiliary lymph nodes. 
Study type: 2 × 2 factorial phase III RCT. Sample 
size: 4646. Start date: May 2002. End date: not 
reported. Status: currently recruiting patients. 
Funding: Cancer and Leukemia Group B, National 
Cancer Institute. Funding amount: not reported.
Lapatinib
N0051189183. This trial is an open-label expanded 
access study of lapatinib and capecitabine therapy 
in women with HER2 (ErbB2) overexpressing 
locally advanced or metastatic breast cancer. 
Study type: multicentre, single-arm, open-label, 
expanded access study. Sample size: approximately 
eight. Start date: September 2006. End date: 
not reported [the study will continue to run and 
enrol subjects until the Medicines and Healthcare 
Products Regulatory Agency (MHRA) gives 
approval for lapatinib]. Status: ongoing. Funding: 
GlaxoSmithKline. Funding amount: not reported.
N0258184664/NCT00347919. A phase II, open-
label, randomised, multicentre trial of GW786034 
(pazopanib) in combination with lapatinib 
(GW572016) compared with lapatinib alone as first-
line therapy in women with advanced or metastatic 
breast cancer with ErbB2 fluorescence in situ 
hybridisation (FISH)-positive tumours. Study type: 
open-label, multicentre, phase II safety/efficacy 
RCT. Sample size: 140. Start date: June 2006. End 
date: not reported. Status: currently recruiting 
patients. Funding: GlaxoSmithKline. Funding 
amount: not reported.
Docetaxel
NCT00408408. A randomised phase III trial of 
neoadjuvant therapy in patients with palpable and 
operable breast cancer, evaluating the effect on the 
pathological complete response (pCR) of adding 
capecitabine or gemcitabine to docetaxel when 
administered before adjuvant chemotherapy (AC)
with or without bevacizumab. Study type: phase 
III RCT. Sample size: 1200. Start date: November 
2006. End date: not reported. Status: currently 
recruiting patients. Funding: National Surgical 
Adjuvant Breast and Bowel Project (NSABP), 
National Cancer Institute. Funding amount: not 
reported.
NCT00391092. A randomised open-label study 
to compare the effect of first-line treatment with 
Avastin in combination with Herceptin/docetaxel 
with Herceptin/docetaxel alone on progression-
free survival in patients with HER2-positive locally 
recurrent or metastatic breast cancer. Study type: 
open-label, phase III, safety/efficacy RCT. Sample 
size: target 100–500. Start date: September 2006. 
End date: not reported. Status: currently recruiting 
patients. Funding: Hoffmann-La Roche. Funding 
amount: not reported.
Bevacizumab
NCT00262067. A multicentre, phase III, 
randomised, placebo-controlled trial evaluating the 
efficacy and safety of bevacizumab in combination 
with chemotherapy regimens in women with 
previously untreated metastatic breast cancer. 
Study type: phase III multicentre RCT. Sample 
size: 1200. Start date: December 2005. End date: 
not reported. Status: currently recruiting patients. 
Funding: Genentech, Hoffmann-La Roche. 
Funding amount: not reported.
NCT00281697. A phase III, multicentre, 
randomised, placebo-controlled trial evaluating the 
efficacy and safety of bevacizumab in combination 
with chemotherapy regimens in women with 
previously treated metastatic breast cancer. Study 
type: phase III multicentre RCT. Sample size: 700. 
Start date: February 2006. End date: not reported. 
Status: currently recruiting patients. Funding: 
Genentech. Funding amount: not reported.
NCT00433511. A double-blind phase III trial 
of doxorubicin hydrochloride liposome and 
cyclophosphamide followed by paclitaxel with 
bevacizumab or placebo in patients with lymph 
node-positive and high-risk lymph node-negative 
breast cancer. Study type: phase III, open-label, 
multicentre RCT. Sample size: 4950. Start date: Appendix 4
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January 2006. End date: not reported. Status: not 
yet open for patient recruitment. Funding: Eastern 
Cooperative Oncology Group, National Cancer 
Institute (NCI), North Central Cancer Treatment 
Group, Cancer and Leukemia Group B. Funding 
amount: not reported.
NCT00373256. A phase III study of SU011248 in 
combination with paclitaxel versus bevacizumab 
with paclitaxel in the first-line advanced disease 
setting in patients having breast cancer. Study type: 
phase III open-label RCT. Sample size: 740. Start 
date: November 2006. End date: not reported. 
Status: currently recruiting patients. Funding: 
Pfizer. Funding amount: not reported.
Trastuzumab
MREC reference MREC01/1/68 (N0258107389, 
N0265110588, N0143108959 N0205108841). The 
HERA trial is a phase III multicentre RCT with 
three arms, comparing 1 and 2 years of Herceptin 
with no Herceptin in women with HER2-positive 
primary breast cancer who have completed 
adjuvant chemotherapy. Sample size: 3192. Start 
date: 1 November 2001. End date: 31 January 
2015. Status: project ongoing. Some funding is 
provided by Roche, as well as NIHR (N0265110588 
only). Funding amount: only reported for 
N0265110588: £140,000 Roche, NIHR £12,500.24.
NCT00381901 (study ID numbers: 
CDR0000509793; INCA-PHARE; INCA-
RECF0146; EUDRACT-2006–000070–67). A 
randomised phase III trial comparing 6 or 12 
months of adjuvant trastuzumab treatment in 
women with non-metastatic breast cancer that 
can be removed by surgery, stratified according 
to participating centre, modality of adjuvant 
chemotherapy (concurrent versus sequential), 
and adjuvant hormonal therapy (yes versus no), 
with a 5-year follow-up. Study design: phase III, 
treatment, randomised, active control. Sample 
size: 7000. Start date: May 2006. End date: not 
reported. Status: currently recruiting. Funding 
provided by the National Cancer Institute, France. 
Funding amount: not reported.
Adjuvant lapatinib and/
or trastuzumab
NCT00490139 (study ID numbers: EGF106708; 
BIG 2–06/N063D); ALTTO: A trial comparing 
lapatinib alone versus trastuzumab alone versus 
trastuzumab followed by lapatinib versus lapatinib 
concomitantly with trastuzumab in the adjuvant 
treatment of patients with HER2/ErbB2-positive 
primary breast cancer. Study design: phase III, 
treatment, randomised, open-label, active control, 
parallel assignment, safety/efficacy study (Breast 
International Group, North Central Cancer 
Treatment Group). Sample size: 8000. Start 
date: May 2007. End date: not reported. Status: 
currently recruiting in some countries. Funded by 
GlaxoSmithKline. Funding amount: not reported.Health Technology Assessment 2008; Vol. 12: No. 32
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published to date
Volume 1, 1997
No. 1
Home parenteral nutrition: a systematic 
review.
By Richards DM, Deeks JJ, Sheldon 
TA, Shaffer JL.
No. 2
Diagnosis, management and screening 
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A review by Selley S, Donovan J, 
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No. 3
The diagnosis, management, treatment 
and costs of prostate cancer in England 
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Moss S, Brown J.
No. 4
Screening for fragile X syndrome.
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No. 5
A review of near patient testing in 
primary care.
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No. 6
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model.
By Faulkner A, Kennedy LG, Baxter 
K, Donovan J, Wilkinson M, Bevan G.
No. 7
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surgery: a systematic review of 
randomised controlled trials.
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A review by Johnson PWM, 
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delay: a systematic review of the 
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By Bekker H, Thornton JG, 
Airey CM, Connelly JB, Hewison J, 
Robinson MB, et al.
No. 2
Handling uncertainty when performing 
economic evaluation of healthcare 
interventions.
A review by Briggs AH, Gray AM.
No. 3
The role of expectancies in the placebo 
effect and their use in the delivery of 
health care: a systematic review.
By Crow R, Gage H, Hampson S, 
Hart J, Kimber A, Thomas H.
No. 4
A randomised controlled trial of 
different approaches to universal 
antenatal HIV testing: uptake and 
acceptability. Annex: Antenatal HIV 
testing – assessment of a routine 
voluntary approach.
By Simpson WM, Johnstone FD, 
Boyd FM, Goldberg DJ, Hart GJ, 
Gormley SM, et al.
No. 5
Methods for evaluating area-wide and 
organisation-based interventions in 
health and health care: a systematic 
review.
By Ukoumunne OC, Gulliford MC, 
Chinn S, Sterne JAC, Burney PGJ.
No. 6
Assessing the costs of healthcare 
technologies in clinical trials.
A review by Johnston K, Buxton MJ, 
Jones DR, Fitzpatrick R.
No. 7
Cooperatives and their primary care 
emergency centres: organisation and 
impact.
By Hallam L, Henthorne K.
No. 8
Screening for cystic fibrosis.
A review by Murray J, Cuckle H, 
Taylor G, Littlewood J, Hewison J.
No. 9
A review of the use of health status 
measures in economic evaluation.
By Brazier J, Deverill M, Green C, 
Harper R, Booth A.
No. 10
Methods for the analysis of quality-
of-life and survival data in health 
technology assessment.
A review by Billingham LJ, 
Abrams KR, Jones DR.
No. 11
Antenatal and neonatal 
haemoglobinopathy screening in the 
UK: review and economic analysis.
By Zeuner D, Ades AE, Karnon J, 
Brown J, Dezateux C, Anionwu EN.
No. 12
Assessing the quality of reports of 
randomised trials: implications for the 
conduct of meta-analyses.
A review by Moher D, Cook DJ, 
Jadad AR, Tugwell P, Moher M, 
Jones A, et al.
No. 13
‘Early warning systems’ for identifying 
new healthcare technologies.
By Robert G, Stevens A, Gabbay J.
No. 14
A systematic review of the role of 
human papillomavirus testing within a 
cervical screening programme.
By Cuzick J, Sasieni P, Davies P, 
Adams J, Normand C, Frater A, et al.
No. 15
Near patient testing in diabetes clinics: 
appraising the costs and outcomes.
By Grieve R, Beech R, Vincent J,
Mazurkiewicz J.
No. 16
Positron emission tomography: 
establishing priorities for health 
technology assessment.
A review by Robert G, Milne R.
No. 17 (Pt 1)
The debridement of chronic wounds: a 
systematic review.
By Bradley M, Cullum N, Sheldon T.
No. 17 (Pt 2)
Systematic reviews of wound care 
management: (2) Dressings and topical 
agents used in the healing of chronic 
wounds.
By Bradley M, Cullum N, Nelson EA, 
Petticrew M, Sheldon T, Torgerson D.
No. 18
A systematic literature review of 
spiral and electron beam computed 
tomography: with particular reference 
to clinical applications in hepatic 
lesions, pulmonary embolus and 
coronary artery disease.
By Berry E, Kelly S, Hutton J, 
Harris KM, Roderick P, Boyce JC, et al.
No. 19
What role for statins? A review and 
economic model.
By Ebrahim S, Davey Smith 
G, McCabe C, Payne N, Pickin M, 
Sheldon TA, et al.
No. 20
Factors that limit the quality, number 
and progress of randomised controlled 
trials.
A review by Prescott RJ, Counsell CE, 
Gillespie WJ, Grant AM, Russell IT, 
Kiauka S, et al.
No. 21
Antimicrobial prophylaxis in total hip 
replacement: a systematic review.
By Glenny AM, Song F.
No. 22
Health promoting schools and health 
promotion in schools: two systematic 
reviews.
By Lister-Sharp D, Chapman S, 
Stewart-Brown S, Sowden A.
No. 23
Economic evaluation of a primary 
care-based education programme for 
patients with osteoarthritis of the knee.
A review by Lord J, Victor C, 
Littlejohns P, Ross FM, Axford JS.Health Technology Assessment 2008; Vol. 12: No. 32
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
49
Volume 4, 2000
No. 1
The estimation of marginal time 
preference in a UK-wide sample 
(TEMPUS) project.
A review by Cairns JA, 
van der Pol MM.
No. 2
Geriatric rehabilitation following 
fractures in older people: a systematic 
review.
By Cameron I, Crotty M, Currie C, 
Finnegan T, Gillespie L, Gillespie W, 
et al.
No. 3
Screening for sickle cell disease and 
thalassaemia: a systematic review with 
supplementary research.
By Davies SC, Cronin E, Gill M, 
Greengross P, Hickman M, Normand C.
No. 4
Community provision of hearing aids 
and related audiology services.
A review by Reeves DJ, Alborz A, 
Hickson FS, Bamford JM.
No. 5
False-negative results in screening 
programmes: systematic review of 
impact and implications.
By Petticrew MP, Sowden AJ, 
Lister-Sharp D, Wright K.
No. 6
Costs and benefits of community 
postnatal support workers: a 
randomised controlled trial.
By Morrell CJ, Spiby H, Stewart P, 
Walters S, Morgan A.
No. 7
Implantable contraceptives (subdermal 
implants and hormonally impregnated 
intrauterine systems) versus other 
forms of reversible contraceptives: two 
systematic reviews to assess relative 
effectiveness, acceptability, tolerability 
and cost-effectiveness.
By French RS, Cowan FM, 
Mansour DJA, Morris S, Procter T, 
Hughes D, et al.
No. 8
An introduction to statistical methods 
for health technology assessment.
A review by White SJ, Ashby D, 
Brown PJ.
No. 9
Disease-modifying drugs for multiple 
sclerosis: a rapid and systematic review.
By Clegg A, Bryant J, Milne R.
No. 10
Publication and related biases.
A review by Song F, Eastwood AJ, 
Gilbody S, Duley L, Sutton AJ.
No. 11
Cost and outcome implications of the 
organisation of vascular services.
By Michaels J, Brazier J, 
Palfreyman S, Shackley P, Slack R.
No. 12
Monitoring blood glucose control in 
diabetes mellitus: a systematic review.
By Coster S, Gulliford MC, Seed PT, 
Powrie JK, Swaminathan R.
No. 13
The effectiveness of domiciliary 
health visiting: a systematic review of 
international studies and a selective 
review of the British literature.
By Elkan R, Kendrick D, Hewitt M, 
Robinson JJA, Tolley K, Blair M, et al.
No. 14
The determinants of screening uptake 
and interventions for increasing uptake: 
a systematic review.
By Jepson R, Clegg A, Forbes C, 
Lewis R, Sowden A, Kleijnen J.
No. 15
The effectiveness and cost-effectiveness 
of prophylactic removal of wisdom 
teeth.
A rapid review by Song F, O’Meara S, 
Wilson P, Golder S, Kleijnen J.
No. 16
Ultrasound screening in pregnancy: 
a systematic review of the clinical 
effectiveness, cost-effectiveness and 
women’s views.
By Bricker L, Garcia J, Henderson J, 
Mugford M, Neilson J, Roberts T, et al.
No. 17
A rapid and systematic review of the 
effectiveness and cost-effectiveness of 
the taxanes used in the treatment of 
advanced breast and ovarian cancer.
By Lister-Sharp D, McDonagh MS, 
Khan KS, Kleijnen J.
No. 18
Liquid-based cytology in cervical 
screening: a rapid and systematic 
review.
By Payne N, Chilcott J, McGoogan E.
No. 19
Randomised controlled trial of non-
directive counselling, cognitive–
behaviour therapy and usual general 
practitioner care in the management of 
depression as well as mixed anxiety and 
depression in primary care.
By King M, Sibbald B, Ward E, 
Bower P, Lloyd M, Gabbay M, et al.
No. 20
Routine referral for radiography of 
patients presenting with low back pain: 
is patients’ outcome influenced by GPs’ 
referral for plain radiography?
By Kerry S, Hilton S, Patel S, 
Dundas D, Rink E, Lord J.
No. 21
Systematic reviews of wound care 
management: (3) antimicrobial agents 
for chronic wounds; (4) diabetic foot 
ulceration.
By O’Meara S, Cullum N, Majid M, 
Sheldon T.
No. 22
Using routine data to complement 
and enhance the results of randomised 
controlled trials.
By Lewsey JD, Leyland AH, Murray 
GD, Boddy FA.
No. 23
Coronary artery stents in the treatment 
of ischaemic heart disease: a rapid and 
systematic review.
By Meads C, Cummins C, Jolly K, 
Stevens A, Burls A, Hyde C.
No. 24
Outcome measures for adult critical 
care: a systematic review.
By Hayes JA, Black NA, Jenkinson C, 
Young JD, Rowan KM, Daly K, et al.
No. 25
A systematic review to evaluate the 
effectiveness of interventions to 
promote the initiation of breastfeeding.
By Fairbank L, O’Meara S, 
Renfrew MJ, Woolridge M, Sowden AJ, 
Lister-Sharp D.
No. 26
Implantable cardioverter defibrillators: 
arrhythmias. A rapid and systematic 
review.
By Parkes J, Bryant J, Milne R.
No. 27
Treatments for fatigue in multiple 
sclerosis: a rapid and systematic review.
By Brañas P, Jordan R, Fry-Smith A, 
Burls A, Hyde C.
No. 28
Early asthma prophylaxis, natural 
history, skeletal development and 
economy (EASE): a pilot randomised 
controlled trial.
By Baxter-Jones ADG, Helms PJ, 
Russell G, Grant A, Ross S, Cairns JA, 
et al.
No. 29
Screening for hypercholesterolaemia 
versus case finding for familial 
hypercholesterolaemia: a systematic 
review and cost-effectiveness analysis.
By Marks D, Wonderling 
D, Thorogood M, Lambert H, 
Humphries SE, Neil HAW.
No. 30
A rapid and systematic review of 
the clinical effectiveness and cost-
effectiveness of glycoprotein IIb/IIIa 
antagonists in the medical management 
of unstable angina.
By McDonagh MS, Bachmann LM, 
Golder S, Kleijnen J, ter Riet G.Health Technology Assessment reports published to date
50
No. 31
A randomised controlled trial 
of prehospital intravenous fluid 
replacement therapy in serious trauma.
By Turner J, Nicholl J, Webber L, 
Cox H, Dixon S, Yates D.
No. 32
Intrathecal pumps for giving opioids in 
chronic pain: a systematic review.
By Williams JE, Louw G, 
Towlerton G.
No. 33
Combination therapy (interferon 
alfa and ribavirin) in the treatment 
of chronic hepatitis C: a rapid and 
systematic review.
By Shepherd J, Waugh N, 
Hewitson P.
No. 34
A systematic review of comparisons of 
effect sizes derived from randomised 
and non-randomised studies.
By MacLehose RR, Reeves BC, 
Harvey IM, Sheldon TA, Russell IT, 
Black AMS.
No. 35
Intravascular ultrasound-guided 
interventions in coronary artery 
disease: a systematic literature review, 
with decision-analytic modelling, of 
outcomes and cost-effectiveness.
By Berry E, Kelly S, Hutton J, 
Lindsay HSJ, Blaxill JM, Evans JA, et al.
No. 36
A randomised controlled trial to 
evaluate the effectiveness and cost-
effectiveness of counselling patients 
with chronic depression.
By Simpson S, Corney R, 
Fitzgerald P, Beecham J.
No. 37
Systematic review of treatments for 
atopic eczema.
By Hoare C, Li Wan Po A, 
Williams H.
No. 38
Bayesian methods in health technology 
assessment: a review.
By Spiegelhalter DJ, Myles JP, 
Jones DR, Abrams KR.
No. 39
The management of dyspepsia: a 
systematic review.
By Delaney B, Moayyedi P, Deeks J, 
Innes M, Soo S, Barton P, et al.
No. 40
A systematic review of treatments for 
severe psoriasis.
By Griffiths CEM, Clark CM, 
Chalmers RJG, Li Wan Po A, 
Williams HC.
Volume 5, 2001
No. 1
Clinical and cost-effectiveness 
of donepezil, rivastigmine and 
galantamine for Alzheimer’s disease: a 
rapid and systematic review.
By Clegg A, Bryant J, Nicholson T, 
McIntyre L, De Broe S, Gerard K, et al.
No. 2
The clinical effectiveness and cost-
effectiveness of riluzole for motor 
neurone disease: a rapid and systematic 
review.
By Stewart A, Sandercock J, Bryan S, 
Hyde C, Barton PM, Fry-Smith A, et al.
No. 3
Equity and the economic evaluation of 
healthcare.
By Sassi F, Archard L, Le Grand J.
No. 4
Quality-of-life measures in chronic 
diseases of childhood.
By Eiser C, Morse R.
No. 5
Eliciting public preferences for 
healthcare: a systematic review of
techniques.
By Ryan M, Scott DA, Reeves C, Bate 
A, van Teijlingen ER, Russell EM, et al.
No. 6
General health status measures for 
people with cognitive impairment: 
learning disability and acquired brain 
injury.
By Riemsma RP, Forbes CA, 
Glanville JM, Eastwood AJ, Kleijnen J.
No. 7
An assessment of screening strategies 
for fragile X syndrome in the UK.
By Pembrey ME, Barnicoat AJ, 
Carmichael B, Bobrow M, Turner G.
No. 8
Issues in methodological research: 
perspectives from researchers and 
commissioners.
By Lilford RJ, Richardson A, Stevens 
A, Fitzpatrick R, Edwards S, Rock F, et al.
No. 9
Systematic reviews of wound 
care management: (5) beds; 
(6) compression; (7) laser therapy, 
therapeutic ultrasound, electrotherapy 
and electromagnetic therapy.
By Cullum N, Nelson EA, 
Flemming K, Sheldon T.
No. 10
Effects of educational and psychosocial 
interventions for adolescents with 
diabetes mellitus: a systematic review.
By Hampson SE, Skinner TC, Hart J, 
Storey L, Gage H, Foxcroft D, et al.
No. 11
Effectiveness of autologous chondrocyte 
transplantation for hyaline cartilage 
defects in knees: a rapid and systematic 
review.
By Jobanputra P, Parry D, Fry-Smith 
A, Burls A.
No. 12
Statistical assessment of the learning 
curves of health technologies.
By Ramsay CR, Grant AM, Wallace 
SA, Garthwaite PH, Monk AF, Russell IT.
No. 13
The effectiveness and cost-effectiveness 
of temozolomide for the treatment of 
recurrent malignant glioma: a rapid 
and systematic review.
By Dinnes J, Cave C, Huang S, 
Major K, Milne R.
No. 14
A rapid and systematic review of 
the clinical effectiveness and cost-
effectiveness of debriding agents in 
treating surgical wounds healing by 
secondary intention.
By Lewis R, Whiting P, ter Riet G, 
O’Meara S, Glanville J.
No. 15
Home treatment for mental health 
problems: a systematic review.
By Burns T, Knapp M, Catty J, 
Healey A, Henderson J, Watt H, et al.
No. 16
How to develop cost-conscious 
guidelines.
By Eccles M, Mason J.
No. 17
The role of specialist nurses in multiple 
sclerosis: a rapid and systematic review.
By De Broe S, Christopher F, 
Waugh N.
No. 18
A rapid and systematic review 
of the clinical effectiveness and 
cost-effectiveness of orlistat in the 
management of obesity.
By O’Meara S, Riemsma R, 
Shirran L, Mather L, ter Riet G.
No. 19
The clinical effectiveness and cost-
effectiveness of pioglitazone for 
type 2 diabetes mellitus: a rapid and 
systematic review.
By Chilcott J, Wight J, Lloyd Jones 
M, Tappenden P.
No. 20
Extended scope of nursing practice: 
a multicentre randomised controlled 
trial of appropriately trained nurses 
and preregistration house officers in 
preoperative assessment in elective 
general surgery.
By Kinley H, Czoski-Murray C, 
George S, McCabe C, Primrose J, 
Reilly C, et al.Health Technology Assessment 2008; Vol. 12: No. 32
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
51
No. 21
Systematic reviews of the effectiveness 
of day care for people with severe 
mental disorders: (1) Acute day hospital 
versus admission; (2) Vocational 
rehabilitation; (3) Day hospital versus 
outpatient care.
By Marshall M, Crowther R, 
Almaraz- Serrano A, Creed F, Sledge W, 
Kluiter H, et al.
No. 22
The measurement and monitoring of 
surgical adverse events.
By Bruce J, Russell EM, Mollison J, 
Krukowski ZH.
No. 23
Action research: a systematic review and 
guidance for assessment.
By Waterman H, Tillen D, Dickson R, 
de Koning K.
No. 24
A rapid and systematic review of 
the clinical effectiveness and cost-
effectiveness of gemcitabine for the 
treatment of pancreatic cancer.
By Ward S, Morris E, Bansback N, 
Calvert N, Crellin A, Forman D, et al.
No. 25
A rapid and systematic review of the 
evidence for the clinical effectiveness 
and cost-effectiveness of irinotecan, 
oxaliplatin and raltitrexed for the 
treatment of advanced colorectal 
cancer.
By Lloyd Jones M, Hummel S, 
Bansback N, Orr B, Seymour M.
No. 26
Comparison of the effectiveness of 
inhaler devices in asthma and chronic 
obstructive airways disease: a systematic 
review of the literature.
By Brocklebank D, Ram F, Wright J, 
Barry P, Cates C, Davies L, et al.
No. 27
The cost-effectiveness of magnetic 
resonance imaging for investigation of 
the knee joint.
By Bryan S, Weatherburn G, Bungay 
H, Hatrick C, Salas C, Parry D, et al.
No. 28
A rapid and systematic review of 
the clinical effectiveness and cost-
effectiveness of topotecan for ovarian 
cancer.
By Forbes C, Shirran L, Bagnall A-M, 
Duffy S, ter Riet G.
No. 29
Superseded by a report published in a 
later volume.
No. 30
The role of radiography in primary 
care patients with low back pain of at 
least 6 weeks duration: a randomised 
(unblinded) controlled trial.
By Kendrick D, Fielding K, Bentley 
E, Miller P, Kerslake R, Pringle M.
No. 31
Design and use of questionnaires: a 
review of best practice applicable to 
surveys of health service staff and 
patients.
By McColl E, Jacoby A, Thomas L, 
Soutter J, Bamford C, Steen N, et al.
No. 32
A rapid and systematic review of 
the clinical effectiveness and cost-
effectiveness of paclitaxel, docetaxel, 
gemcitabine and vinorelbine in non-
small-cell lung cancer.
By Clegg A, Scott DA, Sidhu M, 
Hewitson P, Waugh N.
No. 33
Subgroup analyses in randomised 
controlled trials: quantifying the risks 
of false-positives and false-negatives.
By Brookes ST, Whitley E, Peters TJ, 
Mulheran PA, Egger M, Davey Smith G.
No. 34
Depot antipsychotic medication 
in the treatment of patients with 
schizophrenia: (1) Meta-review; (2) 
Patient and nurse attitudes.
By David AS, Adams C.
No. 35
A systematic review of controlled 
trials of the effectiveness and cost-
effectiveness of brief psychological 
treatments for depression.
By Churchill R, Hunot V, Corney R, 
Knapp M, McGuire H, Tylee A, et al.
No. 36
Cost analysis of child health 
surveillance.
By Sanderson D, Wright D, Acton C, 
Duree D.
Volume 6, 2002
No. 1
A study of the methods used to select 
review criteria for clinical audit.
By Hearnshaw H, Harker R, 
Cheater F, Baker R, Grimshaw G.
No. 2
Fludarabine as second-line therapy for 
B cell chronic lymphocytic leukaemia: a 
technology assessment.
By Hyde C, Wake B, Bryan S, Barton 
P, Fry-Smith A, Davenport C, et al.
No. 3
Rituximab as third-line treatment for 
refractory or recurrent Stage III or IV 
follicular non-Hodgkin’s lymphoma: 
a systematic review and economic 
evaluation.
By Wake B, Hyde C, Bryan S, Barton 
P, Song F, Fry-Smith A, et al.
No. 4
A systematic review of discharge 
arrangements for older people.
By Parker SG, Peet SM, McPherson 
A, Cannaby AM, Baker R, Wilson A, et al.
No. 5
The clinical effectiveness and cost-
effectiveness of inhaler devices used 
in the routine management of chronic 
asthma in older children: a systematic 
review and economic evaluation.
By Peters J, Stevenson M, Beverley C, 
Lim J, Smith S.
No. 6
The clinical effectiveness and cost-
effectiveness of sibutramine in the 
management of obesity: a technology 
assessment.
By O’Meara S, Riemsma R, Shirran 
L, Mather L, ter Riet G.
No. 7
The cost-effectiveness of magnetic 
resonance angiography for carotid 
artery stenosis and peripheral vascular 
disease: a systematic review.
By Berry E, Kelly S, Westwood ME, 
Davies LM, Gough MJ, Bamford JM, 
et al.
No. 8
Promoting physical activity in South 
Asian Muslim women through ‘exercise 
on prescription’.
By Carroll B, Ali N, Azam N.
No. 9
Zanamivir for the treatment of 
influenza in adults: a systematic review 
and economic evaluation.
By Burls A, Clark W, Stewart T, 
Preston C, Bryan S, Jefferson T, et al.
No. 10
A review of the natural history and 
epidemiology of multiple sclerosis: 
implications for resource allocation and 
health economic models.
By Richards RG, Sampson FC, 
Beard SM, Tappenden P.
No. 11
Screening for gestational diabetes: 
a systematic review and economic 
evaluation.
By Scott DA, Loveman E, McIntyre 
L, Waugh N.
No. 12
The clinical effectiveness and cost-
effectiveness of surgery for people with 
morbid obesity: a systematic review and 
economic evaluation.
By Clegg AJ, Colquitt J, Sidhu MK, 
Royle P, Loveman E, Walker A.
No. 13
The clinical effectiveness of 
trastuzumab for breast cancer: a 
systematic review.
By Lewis R, Bagnall A-M, Forbes C, 
Shirran E, Duffy S, Kleijnen J, et al.
No. 14
The clinical effectiveness and cost-
effectiveness of vinorelbine for breast 
cancer: a systematic review and 
economic evaluation.
By Lewis R, Bagnall A-M, King S, 
Woolacott N, Forbes C, Shirran L, et al.Health Technology Assessment reports published to date
52
No. 15
A systematic review of the effectiveness 
and cost-effectiveness of metal-on-
metal hip resurfacing arthroplasty for 
treatment of hip disease.
By Vale L, Wyness L, McCormack K, 
McKenzie L, Brazzelli M, Stearns SC.
No. 16
The clinical effectiveness and cost-
effectiveness of bupropion and nicotine 
replacement therapy for smoking 
cessation: a systematic review and 
economic evaluation.
By Woolacott NF, Jones L, Forbes CA, 
Mather LC, Sowden AJ, Song FJ, et al.
No. 17
A systematic review of effectiveness 
and economic evaluation of new drug 
treatments for juvenile idiopathic 
arthritis: etanercept.
By Cummins C, Connock M, 
Fry-Smith A, Burls A.
No. 18
Clinical effectiveness and cost-
effectiveness of growth hormone in 
children: a systematic review and 
economic evaluation.
By Bryant J, Cave C, Mihaylova B, 
Chase D, McIntyre L, Gerard K, et al.
No. 19
Clinical effectiveness and cost-
effectiveness of growth hormone 
in adults in relation to impact on 
quality of life: a systematic review and 
economic evaluation.
By Bryant J, Loveman E, Chase D, 
Mihaylova B, Cave C, Gerard K, et al.
No. 20
Clinical medication review by a 
pharmacist of patients on repeat 
prescriptions in general practice: a 
randomised controlled trial.
By Zermansky AG, Petty DR, Raynor 
DK, Lowe CJ, Freementle N, Vail A.
No. 21
The effectiveness of infliximab and 
etanercept for the treatment of 
rheumatoid arthritis: a systematic 
review and economic evaluation.
By Jobanputra P, Barton P, Bryan S, 
Burls A.
No. 22
A systematic review and economic 
evaluation of computerised cognitive 
behaviour therapy for depression and 
anxiety.
By Kaltenthaler E, Shackley P, 
Stevens K, Beverley C, Parry G, 
Chilcott J.
No. 23
A systematic review and economic 
evaluation of pegylated liposomal 
doxorubicin hydrochloride for ovarian 
cancer.
By Forbes C, Wilby J, Richardson G, 
Sculpher M, Mather L, Reimsma R.
No. 24
A systematic review of the effectiveness 
of interventions based on a stages-of-
change approach to promote individual 
behaviour change.
By Riemsma RP, Pattenden J, Bridle 
C, Sowden AJ, Mather L, Watt IS, et al.
No. 25
A systematic review update of the 
clinical effectiveness and cost-
effectiveness of glycoprotein IIb/IIIa 
antagonists.
By Robinson M, Ginnelly L, Sculpher 
M, Jones L, Riemsma R, Palmer S, et al.
No. 26
A systematic review of the effectiveness, 
cost-effectiveness and barriers to 
implementation of thrombolytic and 
neuroprotective therapy for acute 
ischaemic stroke in the NHS.
By Sandercock P, Berge E, Dennis M, 
Forbes J, Hand P, Kwan J, et al.
No. 27
A randomised controlled crossover trial 
of nurse practitioner versus doctor-
led outpatient care in a bronchiectasis 
clinic.
By Caine N, Sharples LD, 
Hollingworth W, French J, Keogan M, 
Exley A, et al.
No. 28
Clinical effectiveness and cost – 
consequences of selective serotonin 
reuptake inhibitors in the treatment of 
sex offenders.
By Adi Y, Ashcroft D, Browne K, 
Beech A, Fry-Smith A, Hyde C.
No. 29
Treatment of established osteoporosis: 
a systematic review and cost–utility 
analysis.
By Kanis JA, Brazier JE, Stevenson 
M, Calvert NW, Lloyd Jones M.
No. 30
Which anaesthetic agents are cost-
effective in day surgery? Literature 
review, national survey of practice and 
randomised controlled trial.
By Elliott RA Payne K, Moore JK, 
Davies LM, Harper NJN, St Leger AS, 
et al.
No. 31
Screening for hepatitis C among 
injecting drug users and in 
genitourinary medicine clinics: 
systematic reviews of effectiveness, 
modelling study and national survey of 
current practice.
By Stein K, Dalziel K, Walker A, 
McIntyre L, Jenkins B, Horne J, et al.
No. 32
The measurement of satisfaction with 
healthcare: implications for practice 
from a systematic review of the 
literature.
By Crow R, Gage H, Hampson S, 
Hart J, Kimber A, Storey L, et al.
No. 33
The effectiveness and cost-effectiveness 
of imatinib in chronic myeloid 
leukaemia: a systematic review.
By Garside R, Round A, Dalziel K, 
Stein K, Royle R.
No. 34
A comparative study of hypertonic 
saline, daily and alternate-day rhDNase 
in children with cystic fibrosis.
By Suri R, Wallis C, Bush A, 
Thompson S, Normand C, Flather M, 
et al.
No. 35
A systematic review of the costs and 
effectiveness of different models of 
paediatric home care.
By Parker G, Bhakta P, Lovett CA, 
Paisley S, Olsen R, Turner D, et al.
Volume 7, 2003
No. 1
How important are comprehensive 
literature searches and the assessment 
of trial quality in systematic reviews? 
Empirical study.
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